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Cationic antimicrobial peptides (CAPs) are a very diverse group of amphipathic agents 
that demonstrate broad activity against Gram-positive and -negative bacteria. To overcome the 
obstacle of drug resistance among bacterial pathogens, CAPs have been extensively investigated 
as a potential source of new antimicrobials with novel mechanisms of action that may 
complement current antibiotic regimens. However, the suppression of antimicrobial activity in 
biological conditions (e.g., physiological salt concentrations, serum) constitutes a major 
challenge to the successful development of CAPs for clinical applications. We hypothesized that 
CAPs with optimized amphipathic structures can be designed de novo to enhance antibacterial 
activity and selective toxicity in environments that are generally challenging to host-derived 
peptides. Furthermore, the antibacterial efficacy will positively correlate with length, charge, 
Trp content, and helicity.  
Three specific aims were developed to address this hypothesis. The first aim addressed 
the design of amphipathic peptides to evaluate the influence of helicity, length, and Trp content 
on activity.  Using a base unit peptide approach, we synthesized a multimeric series of 12-
residue lytic base unit (LBU) composed of Arg and Val residues, positioned to form idealized 
amphipathic α-helices. Another series of LBU derivatives (WLBU) was engineered by 
 v
substituting Trp residues on the hydrophobic face. The correlation between length and helicity 
was established by circular dichroism analysis. Bacterial killing assays revealed no appreciable 
increase in activity for peptides longer than 24 residues. In addition, the inclusion of Trp residues 
in the hydrophobic face increased potency and selectivity in a novel co-culture system utilizing 
bacteria and primary cell lines, which led to the selection of WLBU2 as the shortest peptide (24 
residues in length) with the highest potency.  The second objective was to examine the selective 
toxicity of WLBU2 in biological or biologically-derived media. In contrast to the human CAP 
LL37, the peptide WLBU2 displayed potent activity against Pseudomonas aeruginosa in the 
presence of human serum and human blood ex-vivo, with no detectable red blood cell lysis or 
toxicity to human monocytes at all test concentrations. Finally, we demonstrated potent activity 
of WLBU2 in intraperitoneal and intravenous mouse models of Pseudomonas aeruginosa 
infection. WLBU2 not only protected mice prophylactically but also eradicated P. aeruginosa 
from the blood and other tissues at 3 to 4mg/kg. Furthermore, WLBU2 displayed only a minor 
stimulatory effect on inflammatory cytokines, notably IL1-β and TNF-α. Consistent with our in 
vitro studies, the in vivo data provide strong evidence for the potential application of WLBU2 in 
the treatment of systemic infection due to P. aeruginosa.  
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1. CHAPTER 1: Introduction 
1.1. The impact of infectious diseases 
Infectious diseases constitute a worldwide health crisis. Until the 20th century, the 
treatments of many life-threatening microbial diseases (e.g., tuberculosis, the bubonic 
plague) had been highly inadequate (6, 21, 36, 56, 64, 150, 165, 174, 213, 236, 332, 344). 
However, the development of safe and effective vaccines and antibiotics, coupled with 
amelioration of sanitation, resulted in a dramatic decline in infection-related fatalities from 
1900 to 1980 (22, 26, 29, 33-35, 40, 61, 102, 110, 182, 230). This enormous improvement in 
the control of infectious diseases led to the belief that humans were winning the centuries-
long war against infectious microbes. The resurgence of infection-related fatalities over the 
past 25 years, however,  has shown that this optimism was premature (34, 35, 104, 132, 166, 
215, 320, 380). Infectious diseases remain the world’s leading cause of death, ranking third 
among causes of mortality in the United States (134, 389). 
Antibacterial drug resistance is one of the most critical issues in the management 
of infectious diseases (291). Bacteria are among the fastest growing organisms, which 
facilitates rapid genetic changes and the selection of traits allowing adaptation to constantly 
changing ecosystems. The emergence of new phenotypes occurs by alteration of native genes 
or by transfer of genes among organisms (23, 71, 288). These processes are often associated 
with the acquisition of new virulence factors and resistance to currently used antibiotics. 
Hence, organisms re-invent themselves, leading to re-emerging pathogens that may require 
the development of novel therapeutics for eradication (258).  
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Multiple drug resistant (MDR) bacteria have emerged in response to selective 
pressure created by the widespread use of antibiotics (83). The propagation of such 
organisms may occur in hospitals (nosocomial infections), specialized health centers (e. g., 
cystic fibrosis centers), and communities where antibiotics are used inappropriately (77, 130, 
348). Between 1980 and  1992, respiratory tract infections accounted for the largest portion 
of infection-related mortality (28/100,000) in the United States, with an increased death rate 
from 20 to 30 per 100,000 (35, 66). Although acquired immune deficiency syndrome or 
AIDS-related illnesses are among the major, but indirect, causes of this increase in fatalities, 
antibiotic resistance remains a primary concern (137, 291).  
 
1.2. Pseudomonas aeruginosa and antibiotic resistance  
Among major MDR pathogens, a bacterial organism requiring special 
attention is Pseudomonas aeruginosa. This is an opportunistic Gram-negative aerobic rod 
that can be isolated in water, soil, plants, and animals. Because of its ubiquity, the potential 
for frequent exposure to hospitalized patients, and high tendency to become multiply 
resistant to antibiotics, P. aeruginosa poses a serious burden to the clinical management of 
bacterial diseases (85, 137). P. aeruginosa has a high propensity to develop a wide range of 
mechanisms of resistance, which include restricted uptake, drug efflux, and enzymatic 
modification.  
 
1.2.1. Restricted Permeability 
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In comparison to other typical Gram-negative bacteria (e.g., E. coli), P. aeruginosa is 
thought to be inherently less susceptible to several antibiotics by restricting their uptake (435). 
Clinical isolates of P. aeruginosa, namely cystic fibrosis (CF) patient isolates, have a high 
propensity to form an outermost polysaccharide or mucin layer called alginate, which gives 
Pseudomonas a smooth and mucoid appearance (Figure 1) (111, 232). The anionic property of 
this exopolysaccharide matrix may render this organism less sensitive to cationic antibiotics, 
including aminoglycosides and amphipathic peptides (e.g., the polymyxins) (20). Furthermore, 
the outer membrane of P. aeruginosa is spanned by barrel-shaped proteins called porins, which 
are involved in the uptake of small hydrophilic molecules (amino acids, antibiotics, etc.) (220). 
The loss of function of some porin molecules ultimately leads to decreased permeability to 
specific antibiotics (e.g., resistance to imipenem due to loss of oprD) (45, 136, 208, 220). 
Finally, P. aeruginosa has the property of forming biofilms or communities of bacteria that 
adhere to a solid phase. Bacteria existing in a biofilm tend to be less susceptible to antibiotics, 
leading to difficulty in eradicating the infections. Inside the host, biofilms may form on mucosal 
or epithelial surfaces, catheters, and other medical devices. Biofilm formation often leads to 
serious health problems, notably in individuals with chronic infections (e.g., CF patients) and 
patients subjected to certain procedures that require the implantation of prosthetic medical 
devices (e.g., central lines, urinary catheters, etc.) (43, 96, 108, 138, 168, 235, 292). 
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Figure 1. Surface of P. aeruginosa in relationship to antibiotic resistance (Adapted from 
Lambert, 2002) 
Many clinical strains of P. aeruginosa may synthesize an outermost polysaccharide layer called 
alginate (ALG), which may selectively reduce drug permeability. To penetrate the cell, 
antimicrobial agents such must traverse this layer, the lipopolysaccharide (LPS)-containing outer 
membrane (OM), the proteoglycan layer (PG) where ß-lactam antibiotics are inactivated by ß-
lactamases), and the cytoplasmic membrane (CM). Once inside the cells, antimicrobial agents 
 8 
such as aminoglycosides (AG) and quinolones (QN) may be pumped out of the cells. CAPs: 
cationic antimicrobial peptides; ß-L: ß-lactam antibiotics. 
 
 
 
1.2.2. Drug Efflux 
In addition to the restricted permeability of the bacterial envelope, other effective 
mechanisms of resistance can be employed by P. aeruginosa.  One way P. aeruginosa may 
display multiple resistance to antibiotics is by pumping them out of the cell, thereby reducing 
their net uptake (5, 12, 124, 131, 158). This resistance mechanism, which was once confused 
with increased impermeability, is now known to be executed by several complex efflux systems 
expressed by the chromosomal genes mexXY,  mex EF-oprN, mexAB-oprM, and mexCD-oprj. 
The susceptibility of all classes of antibiotics to these efflux pumps, with the exception of 
cationic antimicrobial peptides (CAPs), has been demonstrated (161, 289, 294, 297, 458).  
 
1.2.3. Enzymatic Modification 
In addition to the aforementioned resistance mechanisms, P. aeruginosa is equipped with 
enzymes that can modify specific antibiotics or their targets. Some of these enzymes are derived 
from the expression of chromosomal genes (e.g., the inducible ampC gene expressing β-
lactamase), or of plasmid-mediated genes (39, 42, 149, 284, 296, 319, 364). In some cases, β-
lactamase inhibitors are used clinically to overcome the resistance phenotypes. However, P. 
aeruginosa also develops resistance to β-lactamase inhibitors such as clavulanic acid and 
tazobactam (15, 279, 283, 285). P. aeruginosa may become resistant by acetylation of specific 
antibiotics or of their targets (98). Furthermore, P. aeruginosa may use a rare mechanism of 
resistance against some cationic antimicrobial peptides (e.g., colistin), which is the replacement 
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of a phosphate group with a fatty acyl or aminoarabinose group in the sugar portion of lipid A 
(LPA) (137, 333). These are just a few examples of how this organism modifies its antimicrobial 
target and becomes resistant to a variety of drugs. Please refer to Lambert (2002) for an 
extensive review of antibiotic resistance mechanisms of P. aeruginosa (268). 
 
1.2.4. Pseudomonas aeruginosa Disease 
Based on the status of the host immunity, P. aeruginosa exhibits a very broad range of 
clinical manifestations. P. aeruginosa may colonize the skin, the lungs, and various other tissues. 
In some instances, this organism is able to enter the blood (bacteremia), which may lead to sepsis 
and mortality. This pathogen severely affects patients in intensive care units, burn victims, and 
patients with cancer, ventilator-associated pneumonia (VAP), AIDS, and CF (7, 16, 17, 31, 32, 
37, 38, 41, 51, 54, 57, 60, 85-89, 100, 103, 112, 125, 139, 141-143). The latter is a classical 
example of the significance of antimicrobial resistance in the clinical management of infectious 
diseases.  CF patients have a genetic disorder in the chloride conductance transmembrane 
regulator (CFTR), leading to airway-surface-liquid dehydration, coupled with decreased 
transport and hypersecretion of mucus in response to infections. The mucosal immunity becomes 
compromised, which results in increased susceptibility to bacterial pathogens. Thus, CF patients 
require frequent antibiotic treatments to control their chronic bacterial infections and are 
susceptible to selection for antibiotic resistant isolates.  In fact, most case fatalities in CF are 
associated with infections of the respiratory system, particularly by P. aeruginosa (92, 106, 114, 
115, 119, 120, 122, 128, 129, 151, 157, 170, 171). Hence, the occurrence of antibiotic resistance 
AG 
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underscores the need for developing novel antimicrobial agents to complement current 
antimicrobial regimens.   
1.3. Cationic Antimicrobial Peptides 
1.3.1. In Search of Novel Antimicrobial Therapeutics 
The evolutionary success of multicellular organisms is largely due to the development of 
very diverse and elaborate defense systems, known collectively as host immunity. The epithelial 
surfaces of plants and animals are continuously exposed to potentially invasive and deadly 
pathogens. It is essential that the host immunity provide a mechanism of rapid clearance or 
inactivation of most of these microbes. An essential and functionally conserved component of 
the host immunity that fulfills this role is a group of agents known as antimicrobial peptides.  
The majority of these antibiotics are highly cationic and tend to fold into amphipathic structures 
(18, 50, 63, 67, 90, 219, 342, 394). Thus, they are often referred to as cationic amphipathic 
peptides or CAPs (162). 
Most of the support for the antimicrobial properties of CAPs has come from intense 
investigations during the last 20 years. However, the field of antimicrobial peptides began in the 
late 19th and early 20th centuries with the discovery of complement and several other basic 
antibacterial tissue factors. Complement, initially termed alexin, was first described as a 
thermolabile substance that was specific for Gram-negative bacteria and that lost its activity in 
defibrinated blood. Further studies characterized alexin as a complex system of several 
components then referred to as the complement (318, 377). With the recent characterization of 
the antimicrobial properties of C3a, the complement can be now associated with antimicrobial 
peptides research (317). In 1922, Alexander Fleming reported the isolation of a ‘remarkable 
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bacteriolytic element’ of leukocytic granules derived from the nasal secretion of a patient with 
acute coryza. He elucidated the antibacterial properties of this heat-stable basic protein, which he 
termed lysozyme (184). As an enzyme that digests bacterial cell walls, lysozyme is not a typical 
antimicrobial peptide. However, antibacterial properties of nonenzymatic heat-stable basic 
proteins with high Arg or Lys contents (e.g., protamine, histones) were also reported (377). 
During this period of early discoveries, investigators clearly made the association between the 
cationicity of these proteinaceous agents and their selective interactions with the negatively 
charged bacterial surface (187). Further, the natural resistance to certain microbial pathogens due 
to the presence of these basic tissue factors was established (377). In the 1950s and 1960s, 
Watson, Zeya, and others characterized the interactions between Gram-negative bacterial 
membranes or nucleic acids and neutrophil lysosomal fractions, which included Arg-rich 
proteins (75, 76, 448, 451, 453). In 1975, Weiss et al. not only distinguished between the activity 
of a proteinaceous lysosomal fraction and that of lysozyme, but also characterized the 
electrostatic nature of the peptide interaction with the surface of sensitive bacteria using divalent 
cations as competitive inhibitors (423).  These studies provided the earliest insight on the 
mechanisms of action of basic antimicrobial peptides. However, it took at least two more 
decades to elucidate the identity, structural diversity, antimicrobial mechanisms, and the 
environmental factors affecting the biological activities of these peptides. 
By 1980, infectious disease experts were becoming increasingly aware of the problem of 
antibiotic resistance (1, 2, 4, 97). To address this issue, intensive investigation had been initiated 
to identify and characterize alternative sources of agents with novel antimicrobial mechanisms. 
Thus, among the areas of primary focus were the components, functions, and mechanisms of the 
host immunity of various species (vertebrates and invertebrates). Importantly, the components of 
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the insect immunity were likely candidates for novel antimicrobial factors, as they had been 
already described and known to exclude antibody molecules and lymphocytes (180, 240, 335). In 
insects, a well-characterized mechanism of resistance to infectious pathogens is lysozyme-
dependent; however, the restriction of lysozyme efficacy to select gram-positive bacteria led to 
the prediction of the presence of other host factors that could be active against a wide range of 
bacteria (82, 183, 249, 259, 261). In the early 1980s, the preliminary observation that the cell-
free hemolymph of immunized insects kills bacteria led Boman and colleagues to isolate 2 basic 
proteins (cecropins A and B). Cecropin peptides were later identified in other species, and their 
broad activity and selective toxicity toward Gram-negative bacteria characterized (81, 82, 241, 
248, 336, 385, 428). During that time, another peptide (mellitin) from bee venom was described 
as both bactericidal and toxic to red blood cells (408). In contrast, the cecropins did not display 
significant hemolytic property. The primary sequences of these cationic antimicrobial peptides 
(CAPs), which displayed high selective toxicity against bacteria, were among the first to be 
elucidated. A few years later, Dr. Michael Zasloff, while performing experimental surgery on the 
African frog Xenopus larvae, was surprised by the resistance to infections afforded by predicted 
substances in the frog skin.  In 1987, he reported the isolation and activity of magainin 1 and 
magainin 2 against several organisms. The peptides displayed the highest potency against 
Escherichia coli, Klebsiella pneumoniae, Pseudomonas putida, and Staphylococcus epidermidis 
(446). An important lesson learned from this study was that the activities of these peptides were 
dependent on the test organism.  
Similar to the studies that led to these aforementioned discoveries, several were initiated 
on antibacterial properties of neutrophil azurophil granules in mammals, which ultimately 
resulted in the identification of a group of antimicrobial peptides known as the defensins. In a 
 13 
series of experiments consisting of lysosomal fractionation, antimicrobial killing assays, protein 
purification, etc., Gantz, Lehrer, and colleagues isolated the rabbit microbicidal cationic proteins 
(MCP) and the human neutrophil proteins (HNP), characterized their antibacterial, antiviral, and 
antifungal activities, and elucidated their primary amino acid sequences. These newly identified 
peptides were classified as mammalian defensins.  These studies were remarkable for bringing to 
light not only the existence of mammalian CAPs, but also their antifungal, antiparasitic, and 
antiviral properties (14, 84, 148, 276, 278, 311, 362, 402, 415, 424). Furthermore, Tomas Gantz, 
using several techniques including enzyme immunoassay, polyacrylamide gel electrophoresis, 
etc., was able to elucidate the secretory mechanism of human neutrophil defensins and quantify 
the amount of peptide (4 to 5µg/106 PMN) released in vitro by neutrophils in response to stimuli 
(e.g., phorbol myristate acetate) (194). The discovery of the cecropins, magainins, and 
mammalian defensins marked a turning point in the advancement of the field of antimicrobial 
peptides research.  
After hundreds of peptides had already been identified, a newly discovered family of 
CAPs, the cathelicidins, became (along with the defensins) the subject of intense 
investigations. Similar to the defensins, the cathelicidins are found in mammals, including 
human. These gene-encoded peptides are synthesized as inactive precursors consisting of a 
secretory signal sequence, a highly conserved 5’ terminus region (propeptide), and species-
specific, highly diverse antimicrobial sequences (Figure 2) (441). The study of these two 
peptide families (defensins and cathelicidins), coupled with that of engineered and other 
host-derived peptides, has significantly enhanced the understanding of the secretory and 
antimicrobial mechanisms of CAPs, the influence of different environments on activity, and 
their multiple roles in host immunity (30, 147, 193, 201, 295, 328, 378, 398, 411). To date, 
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more than 1000 natural antimicrobial peptides have been identified, and most (if not all) 
organisms reportedly use antimicrobial peptides as part of their immune systems.   
 
Figure 2. The Gene structure of a typical antimicrobial peptide (adapted from Zaiou and  
Gallo, 2002) (439).  
   
1.3.2. Structural Diversity 
One of the surprising features of antimicrobial peptides is the conservation of 
antimicrobial functions despite their structural diversity. Mammalian antimicrobial peptides are 
generally synthesized as part of a protein with no antimicrobial function. As illustrated in Figure 
2, there is a signal sequence that serves to guide the protein to secretory vesicles. The active form 
of the peptide is released after protease-specific digestion (225, 308, 328, 374, 411). The highly 
conserved property of a particular family of CAPs is the anionic propeptide sequence, which 
electrostatically interacts with the antimicrobial domain and inhibits its activity until cleavage 
occurs by specific proteases (287). The propeptide is sometimes used as a basis for classification. 
For instance, in the inactive form of mammalian cathelicidins, the propeptide is a highly 
conserved cathelin (cathepsin protease inhibitor family)-like protein, but the cathelicidins and 
other CAP families can be further grouped according to their native secondary conformations (α-
helix, β-sheet, loop) or amino acid content (58, 63, 72, 95, 272, 274). As demonstrated by 
structural analyses of CAPs in the presence of liposomes or membrane mimitope solvents (e.g., 
Trifluoroethanol) using NMR or circular dichroism, the cathelicidins can specifically adopt 
different types of secondary conformations. For example, the human cathelicidin LL-37 folds 
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into a α-helix, whereas the porcine protegrins assume β-sheet and loop structures (95, 264, 272, 
274, 432). Cathelicidins are also distinguished according to amino acid contents (e.g., the Pro-
rich PR-39 and Trp-rich indolicidin) (10, 190, 345). Unlike the cathelicidins, the defensins, a 
major family of CAPs, tend to adopt only β-sheet conformations. A major reason for this highly 
conserved native structure in defensins is the presence of 6 Cys residues, which form 3 
disulphide bridges that stabilize the β-strands (200, 243, 282, 376).  
A common property of antimicrobial peptides is their tendency to fold into amphipathic 
structures. The diversity of the peptide primary structures is due to the necessity of the host 
immunity to successfully adapt to different environments by retaining its efficacy against 
specific microbial pathogens. Hence, the conservation of antimicrobial functions is highly 
dependent on the amphipathic properties of CAPs and not necessarily on the retention of primary 
sequence homology. Yet amphipathicity is highly influenced by the amino acid composition and 
arrangement in the primary sequence, which affects the specificity of antimicrobial activity in a 
given environment. For instance, the defensins of the human airway have evolved to be 
optimally active in hypotonic environments. This explains why their antibacterial activity is 
suppressed in abnormally higher salt concentrations (e.g., the CF airway) (47, 48). Similarly, 
antimicrobial activities of most host-derived CAPs are markedly inhibited in serum or blood-
derived matrices (381). An important concept that has been described to explain structural 
diversity in the face of conservation of antimicrobial activity is immunorelativity, or immunity in 
the context of specific environments and invading pathogens. Immunorelativity is the basis for 
the specific tissue distribution of CAPs in a particular organism. For instance, in humans the 
predominant antimicrobial peptides of the skin (e.g., LL37, β-defensins. etc.) may be different 
from those of the mucosal surfaces of the oral cavity, the reproductive system, and others (196, 
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316, 356, 412). These different environments are likely to be exposed to different pathogens and 
to have different fluid compositions over millions of years of evolution. Thus, the diversity of 
peptide primary sequences, coupled with the conservation of the amphipathic properties, is 
mainly dictated by the host environment, including specific pathogens that are likely to be 
associated with that environment.  
 
1.3.3. Biological Properties 
The field of antimicrobial peptides is a highly neglected aspect of immunology in the 
sense that it is rarely, if ever, addressed in typical immunology textbooks. Ironically, 
antimicrobial peptides represent the first line of defense against invading pathogens by providing 
a rapid and effective defense mechanism against potentially harmful pathogens. Although some 
antimicrobial peptides (e.g., the human neutrophil peptides) play an essential role in circulating 
neutrophil-mediated microbial killing, most pathogens usually face the mucosal-derived 
antimicrobial peptides prior to the intervention of circulatory phagocytes (44, 46, 49, 147, 164, 
175, 176, 181). While the study of microbial killing mediated by neutrophils and macrophages 
has primarily brought to light the importance of CAPs in the innate immunity, the discovery of 
epithelial-specific distribution of antimicrobial peptides indicates a more essential and larger role 
of mucosal surfaces in host immunity than early reports on antimicrobial peptides might have 
suggested (46, 242, 329). The interactions of microbial pathogens with local phagocytes or 
epithelium-derived CAPs are likely to precede the events leading to the activation of circulatory 
phagocytes and subsequent microbial killing by these phagocytes. 
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The epithelial surfaces are continuously exposed to microbial pathogens in the 
environment. The primary task of the host immunity is to prevent the colonization and invasion 
of the host epithelia by potential pathogens while sparing the organisms that comprise the normal 
flora. Thus, epithelial cells have the ability to express and secrete antimicrobial peptides either 
constitutively or in response to microbial presence. The inducible expression of CAPs can be 
stimulated either by inflammatory cytokines or by the interactions of microbial organisms and 
endotoxins with the epithelial cells (409). Hence, the human defensins-5, 6 (HD-5, 6) and human 
β-defensin-1 (hBD-1) are constitutively expressed and secreted in the genitourinary and the 
gastrointestinal tracts (HD-5, 6 and hBD-1), whereas hBD-2 expression is inducible in the skin, 
lungs, and several other tissues. Particular noteworthy is the fact that the constitutive expression 
of a CAP in a specific tissue does not exclude its modulation under certain conditions or in other 
tissues (135, 322, 323, 337, 338, 375, 382, 412). In epithelial cells, the active forms of CAPs are 
released into the extracellular milieu after cleavage of the inactive protein by a specific 
proteolytic enzyme (357).  However, a significant portion of antimicrobial peptides localized in 
phagocytic granules kill their target intracellularly. Similar to the cathelicidins and the defensins 
of epithelial cells, these peptides are synthesized as inactive proteins. Nevertheless, the post-
translational processing leading to the active structures occurs during the myeloid cell 
differentiation into granulocytes. In the activated phagocytes, the peptides reach their targets by 
the fusion of the phagocytic granules with the phagolysosomes, although extracellular release 
may occur (46, 78, 101, 167, 198, 200, 202, 229, 273-275, 277, 321, 328, 363, 427).  
A broad spectrum of microbial targets has been identified either by mechanistic studies of 
non-oxygen mediated microbial killing of neutrophils or by standard in vitro microbial killing 
assays with specific CAPs. Antimicrobial peptide activity of a given CAP may be specific to a 
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wide range of Gram-negative or -positive bacteria, or both. Other microbial targets may include 
atypical bacteria, parasites, fungi, and enveloped viruses (197, 443-445). The structural 
requirements for optimal activity against specific environment-associated pathogens have driven 
the compartment-specific differentiation of CAPs. Thus, LL37 and the defensins of circulating 
phagocytes display broad activity against bacteria, fungi, parasites, and enveloped viruses. The 
defensins of alveolar macrophages or airway epithelial surface are highly potent against 
pathogens of the airway. Similarly, the activity of CAPs localized to the other mucosal surfaces 
(reproductive tract, the urinary tract, and others) is likely to be optimal for pathogens associated 
with those tissues.  
The antimicrobial properties of CAPs are demonstrated in the context of the host 
immunity as a whole. Studies of the best-known human antimicrobial peptide families, the 
defensins and the cathelicidin, LL37, show that CAPs can promote leukocyte chemotaxis and 
phagocytosis (e.g., LL37 and α-defensins) (195, 263, 272, 314, 315, 440).  For instance, the 
human β-defensin hBD-2 displays CCR6-mediated chemotactic activities specific to immature 
dendritic cells and T lymphocytes, while LL37 demonstrates a similar chemotactic activity on T 
cells, neutrophils, and monocytes by interacting with the formyl-peptide receptor-like 1 (FPRL1) 
(159, 203, 238, 315, 399, 431). The ability of these peptides to upregulate the level of 
inflammatory cytokines has been demonstrated in vitro and in vivo (413, 414). Therefore, it is 
not surprising that, as mediators of inflammation, they cause tissue injury in the setting of a local 
infection. Further, these peptides play a series of other roles such as modulating adaptive 
immunity and wound healing, suppressing hormonal activity and fibrinolysis. For a more 
extensive discussion of the multiple biological functions of CAPs, please refer to the reviews by 
Hancock, Lehrer, and others (156, 222, 358).   
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1.3.4. Mechanisms of Selective Toxicity 
An essential property of a safe antimicrobial factor is toxicity against its microbial targets 
without harming the host. The ubiquity of antimicrobial peptides suggests that their antimicrobial 
property needs not be associated with host toxicity. However, the specific tissue distribution in a 
given animal species indicates that host toxicity may also depend on the environment. As 
previously discussed, the peptides are synthesized as inactive proteins prior to exposure to their 
targets, and CAP activation by post-translational processing ensures that the cellular membrane 
structures are protected from any contact with the active peptides prior to reaching their 
microbial targets.  For the peptides that are secreted in specific extracellular milieu, the peptide 
concentration may be effective against specific pathogens but sublethal to host cells. In addition 
to environmental influence, there are some fundamental structural properties that may generally 
render microbial organisms more susceptible than the host to antimicrobial peptides. This 
antimicrobial selectivity, although not completely understood for several antimicrobial peptides, 
is partially explained by differences in lipid composition of eukaryotic and bacterial cell 
membranes (59, 70). Eukaryotic membranes are likely to form hydrophobic (weaker than 
electrostatic) interactions with CAPs due to the lower proportion of negative lipids and the 
presence of cholesterol in their membrane outer leaflet.  In general, when CAPs (e.g., magainins, 
cecropins, LL37) are dissolved in aqueous solvents, they demonstrate a disordered structure or 
random coil as revealed by circular dichroism analysis. On the other hand, in the presence of 
increasing concentrations of a membrane mimitope solvent or liposomes there is a concomitant 
increase in the propensity of these peptides to form  α-helices (67, 260, 324). Peptides with other 
types of native structures, such as the defensins (β-sheet) and protegrins (β-sheet and loop), 
behave similarly (200, 264). Evidence for electrostatic interactions with variably charged 
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liposomes is also provided by other established methods, including surface plasmon resonance 
(SPR) spectroscopy or Biacore analysis. Based on these studies, antimicrobial peptides are 
known to form stronger interactions with bacterial endotoxins and negatively charged surface 
phospholipids (e.g., LPS, lipotheic acids, phosphatidyl glycerol, etc.) than with zwitterionic and 
cholesterol-containing liposomes (153, 212, 231, 455).  
Similarly, higher negative:zwitterionic phospholipid ratios enhance CAP-induced leakage 
of fluorescent molecules (e. g., calcein) from model membranes (105, 123, 207, 299, 300, 456). 
Thus, electrostatic interactions between CAPs and negative lipids on the bacterial surface may 
provide the energy that drives CAP insertion in microbial membranes. Another key modulator of 
CAP-membrane interactions is hydrophobicity. While cationicity is the primary determinant of 
antibacterial selectivity, hydrophobicity probably enhances activity against Gram-positive 
organisms and may compromise antimicrobial selectivity if raised beyond an optimal level. 
Hence, the amphipathic nature of CAPs, or the combined structural contributions of 
hydrophobicity and cationicity are critical to antibacterial selectivity (154, 155, 206, 217, 262). 
What remains to be established, however, is whether the strength of this initial peptide-
membrane interaction correlates with antimicrobial activity. 
An area of controversy is the mechanism of microbial killing. There are several models 
of the killing mechanism, each supported by the study of specific groups of peptides. One of the 
earliest approaches consists of biochemical analyses of membrane permeabilization by cationic 
peptides. In these studies, bacteria are exposed to peptides in the presence of an impermeable 
substrate (ONPG) for the intracellular enzyme β-galactosidase.  The increased activity of this 
enzyme as a function of time or peptide concentration is indicative of cytoplasmic membrane 
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permeabilization. Fluorescence spectroscopy studies using peptide-mediated 1-N-
phenylnapthylamine (NPN) uptake (indicating outer membrane permeabilization) or calcein 
released from variably charged artificial membrane further support the formation of pores 
leading to leakage of cellular content (207, 266, 271, 298, 299, 456). These studies help to 
establish the ability of some peptides to permeabilize either the outer membrane only (e.g., 
polymyxin B) or both outer and inner bacterial membranes (e.g., lentiviral lytic peptide 1 or 
LLP-1) (331). Consistent with the biochemical and fluorescent analyses is the observation of 
bacterial membrane damage (disorganization, blebbing, etc.) by electron microscopy. These 
studies led to the partial evaluation of the antimicrobial mechanism of the pore-forming peptides. 
However, to elucidate the steps involved in membrane lysis, the use of other methods is 
necessary. 
With advanced structural analyses using oriented CD, NMR, and X-ray crystallography 
among other techniques, investigators are able to determine the important steps involved in 
membrane penetration. Three models for lytic mechanisms have been distinguished. In the 
barrel-stave model, some amphipathic α-helical peptides may perpendicularly penetrate the lipid 
bilayer with the hydrophilic regions of aggregated molecules facing the center of the pore and 
the hydrophobic domains directly in contact with the fatty-acyl groups (lipid core of the bilayer) 
(172, 269, 270, 383, 433). Yet some other helical peptides may accumulate on the surface of the 
bilayer in a head-to-tail fashion by lying in parallel to the outer and inner leaflets, leading to 
formation of micelles as observed for detergents. This “carpet-like” bacterial killing is mainly 
attributed to the antimicrobial peptide ovispirin, an 18-mer CAP with broad-spectrum 
antibacterial activity (366, 367, 429, 430). A third mechanism, the toroidal model, shares some 
common features with the other two. It is similar to the barrel mechanism by the perpendicular 
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insertion of the peptide leading to the formation of pores but differs from this model by the 
continuous association of the peptide with the lipid head groups. Similar to the carpet model, the 
inner lining of the pore consists of the peptide and the associated lipid head groups. Examples of 
CAPs inducing this type of membrane pore are provided by the magainins (frog skin), protegrins 
(porcine cathelicidin), and mellitin (antibacterial and hemolytic CAP from bee venom) (19, 290, 
379, 433).  
A different view on the mechanism of action of CAPs involves the penetration of the cell 
followed by electrostatic interactions with the negatively charged DNA and RNA. Support for 
this type of model comes from studies of buforin II (histone-derived peptide), indolicidin, and 
other peptides, which indicate that microbial killing occurs by inhibition of the major vital 
intracellular processes (e.g., DNA replication), sometimes coupled with the absence of pore 
formation. This alternative view is strongly supported by the identification of a hinge region in 
Buforin II, which promotes cellular penetration of chimeric CAPs consisting of the hinge 
sequence and a pore forming sequence (179, 310, 313, 326, 334, 388, 390). 
 
1.3.5. Engineered Antimicrobial Peptides and Potential Applications 
One of the most important lessons we have learned from the studies of host-derived 
peptides is that antimicrobial activity and selective toxicity essentially depend on amphipathicity 
and environmental conditions. The diversity of CAPs, dictated by the necessity for optimal 
antimicrobial activity in a given environment, indicates that the engineering of a peptide with 
universal applications is highly unlikely. Based on this understanding, several attempts have 
been made to develop CAPs for specific applications. Hence, magainin derivatives were first 
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generated to treat diabetic foot ulcer (205, 210). Unfortunately, this project prematurely ended 
because the approval for clinical use was not granted by the Food and Drug Administration 
(FDA). However, the polymyxins have been used clinically against P. aeruginosa in severe cases 
of gram-negative bacterial sepsis. The latest polymyxin derivative, colistin, is used either IV or 
by inhalation in the treatment of respiratory infections caused by P. aeruginosa in CF patients, 
but there is major toxicity (particularly nephrotoxicity) associated with its systemic use (65). 
Derivatives of histatins, a family of salivary antimicrobial peptides, have been successfully 
engineered and tested for the treatment of oral infections (346). In most cases, the development 
of CAPs for topical applications is dictated by the suppression of activity in biological fluids 
(e.g., blood, plasma, or serum). The potential of antimicrobial peptides for clinical applications is 
yet to be fully explored.  
Based on this understanding, we hypothesized that cationic antimicrobial peptides 
(CAPs) with optimized amphipathic structures could be engineered de novo to enhance 
antibacterial activity and selective toxicity in environments that are generally challenging to 
host-derived peptides. Furthermore, antibacterial efficacy would positively correlate with length, 
helicity, charge, and Trp content.  
1.4. Specific Aims 
1.4.1. Specific Aim 1 
To design de novo engineered cationic amphipathic peptides (eCAPs) and evaluate 
their antimicrobial activity.  We evaluated the functional properties of a series of de novo 
engineered CAPs that contain multimers (2, 3, & 4 repeats) of a 12-mer lytic base unit 
(LBU) composed only of Arg and Val residues or multimers of a modified unit (WLBU) 
that contains specific Trp substitutions, both arranged to form an idealized amphipathic α-
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helix.  Peptide antimicrobial activities were correlated with length, helicity, and Trp content 
to establish the structural determinants of antimicrobial activity.  
 
1.4.2. Specific Aim 2 
To examine the mammalian cytotoxicity and sensitivity of select peptides to varying 
salt concentrations and biological fluids by bacterial killing assays (BKA). Initial 
characterizations of CAP cytotoxicity in our lab and others have been based on human 
erythrocyte lysis assays (371, 396). While easy to perform, the relevance of these assays to 
host-pathogen interactions in biological fluids and specific infections remains uncertain.  
Therefore, we have developed a series of novel selective toxicity assays by measuring the 
selective toxicity of candidate peptides in a mixed culture of bacteria and human cells. In 
these assays, bacterial and host cell viability are monitored as a function of peptide added to 
assess CAP selective toxicity.  
 
1.4.3. Specific Aim 3 
To evaluate the antibacterial efficacy of select peptides in experimental mouse model 
of P. aeruginosa bacteremia. To complement our in vitro studies, antimicrobial effects of 
our lead peptide were evaluated in two acute infection mouse models. In the intraperitoneal 
(IP) (245) model, the peptide WLBU2 was administered intravenously 1h after IP injection 
of bacteria.  An intravenous (IV) infection model was then developed to further examine 
the efficacy of WLBU2. In this model, the prophylactic potential and the therapeutic effects 
of the peptide were determined in a dose-dependent manner. Outcomes were evaluated and 
compared by monitoring mouse survival over time, the level of bacterial cfu per mL blood 
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or per gram of tissue (liver, lungs, and spleen), and the level of inflammation by 
histopathology and ELISA for assessment of cytokine profiles in isolated serum samples. 
These novel animal models provide important information on the in vivo potential of 
WLBU2 and serve as a basis for consideration of human clinical trials to treat P. 
aeruginosa septicemia.  
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The following two chapters are published articles with minor modification to formatting 
used with permission of ASM Press: 
1. Deslouches B, Phadke SM, Lazarevic V, Cascio M, Islam K, Montelaro RC, Mietzner TA. De novo 
generation of cationic antimicrobial peptides: influence of length and tryptophan 
substitution on antimicrobial activity. Antimicrob Agents Chemother. 2005 Jan;49(1):316-22. 
 
2. Deslouches B, Islam K, Craigo JK, Paranjape SM, Montelaro RC, Mietzner TA. Activity of the de 
novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in 
human serum and whole blood: implications for systemic applications. Antimicrob Agents 
Chemother. 2005 Aug;49(8):3208-16.  
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2. CHAPTER 2: DE NOVO GENERATION OF CATIONIC ANTIMICROBIAL 
PEPTIDES:  INFLUENCE OF LENGTH AND TRYPTOPHAN SUBSTITUTION ON 
ANTIMICROBIAL ACTIVITY 
 
2.1. Abstract 
Studies of lentiviral lytic peptide 1 (LLP1) of HIV-1 transmembrane glycoprotein gp41 and 
other host-derived peptides indicate that antimicrobial properties of membrane-active peptides are 
markedly influenced by their cationic, hydrophobic, and amphipathic properties.  Many common 
themes, such as Arg composition of the cationic face of an amphipathic helix and the importance of 
maintaining a hydrophobic face have been deduced from these observations.  These studies suggest 
that a peptide with these structural properties can be derived de novo using only a few strategically 
positioned amino acids.   However, the effects of length and helicity on antimicrobial activity and 
selectivity have not been objectively evaluated in the context of this motif. To address these 
structure-function issues, multimers of a 12-residue lytic base unit (LBU) peptide composed only of 
Arg and Val residues aligned to form idealized amphipathic helices were designed. Bacterial killing 
assays and circular dichroism analyses revealed a strong correlation between antibacterial activity, 
peptide length, and the propensity to form α-helices in solvents mimicking the environment of a 
membrane.  Increasing peptide length beyond two LBUs (24-residue peptides) resulted in no 
appreciable increase in antimicrobial activity.  Derivatives (WLBU) of the LBU series were further 
engineered by substituting Trp residues in the hydrophobic domains. The 24-residue WLBU2 
peptide was active at physiologic NaCl concentrations against Staphylococcus aureus and mucoid 
and non-mucoid strains of Pseudomonas aeruginosa.  Further, WLBU2 displayed the highest 
antibacterial activity of all peptides evaluated in this study using a co-culture model of P. aeruginosa 
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and primary human skin fibroblasts.  These findings provide fundamental information toward the de 
novo design of an antimicrobial peptide useful for the management of infectious diseases. 
  
2.2. Introduction 
Despite the establishment of safe and effective antibiotics, the management of infectious 
diseases remains a worldwide public health concern. One untapped resource of novel 
antimicrobial agents, evolutionarily proven as anti-infectives, are the host derived antimicrobial 
peptides (218, 221).  In vertebrates, insects, and even bacteria, these compounds represent the 
first line of defense against pathogens challenging the host (221). These peptides commonly 
adopt an amphipathic conformation in which positively charged and hydrophobic groups 
segregate onto opposing faces of α-helices, ß-sheets, or other tertiary structures (343). These 
general structural properties confer an ability to disrupt or traverse a phospholipid membrane. 
The spectrum of different amino acid side chain chemical properties affords a variety of peptide 
sequences to present a cationic amphipathic helical peptide. As a result, hundreds of different 
natural cationic antimicrobial peptides (CAPs) with widely varying sequences have been 
described.   The diversity of antimicrobial peptides is likely a consequence of each peptide 
evolving to function in a particular environment against a specific subset of microbial pathogens. 
We have previously reported the conservation of a peptide derived from the extreme C-
terminus of the HIV-1 transmembrane protein that is referred to as the lentivirus lytic peptide 1 
(LLP1) (302).  Like other membrane interactive peptides, LLP1 is predicted to have an 
amphipathic α-helical structure and may be involved in calmodulin binding (303, 397, 438) and 
natural endogenous reverse transcriptase (NERT) activities of HIV-1 (454).  Investigations of the  
 29 
 
Hydrophobic
Cationic
R11
V5
V9
V2
V6V10V3
R1
R4
R7
LBU1
R12R8
R1 V5
V16
V6
V2
W9
V13
V10V3
W17
WLBU4
R8
R7
R18
R15
R4
R11
R14
W35
V24
V31
V20
W27
V28V21
V34
V23
V39 V46
V42
V38
W45
V41
R30R19
R26
R33
R29
R36
R25
R32
R12
R22
R48
R44
R47
R43
R40
R37
A
B
* Molecular weight in Daltons
Peptide Sequence *MW (D)
LBU-1                                                               RVVRVVRRV VRR    1,549
WLBU-1                                                               RVVRVVRRWVRR    1,636
LBU-2                                                               RR VVRRVRRV VRRVVRVVRRV VRR    3,138
WLBU-2                                                               RRWVRRVRRWVRRVVRVVRRWVRR    3,398
LBU-3                                    VRRV VRRVVRVVRRV VRRVRRV VRRVVRVVRRV VRR   4,612
WLBU-3                                      VRRVWRRVVRVVRRWVRRVRRWVRRVVRVVRRWVRR   4,961
LBU-4    RVVRVVRRVV RRVRRV VRRVVRVVRRV VRRVRRVV RRVVRVVRRVVRR  6,145
WLBU-4    RVVRVVRRWVRRVRRVWRRVVRVVRRWVRRVRRWVRRVVRVVRRWVRR   6,579
 
Figure 3. Peptide design 
 
The cationic amphipathic peptides were designed as demonstrated in the helical wheel diagrams 
(A). Arg, Val, and Trp residues were arranged to form idealized amphipathic α-helices, with the 
hydrophilic and hydrophobic faces indicated in clear and shaded circles, respectively. The 12- 
and 48-mers LBU1 and WLBU4 are shown as representatives of the LBU and WLBU series, 
respectively. (B) Primary sequences of the LBU and WLBU peptides used in this study are 
shown. The shortest peptide forms one lytic base unit (LBU1) of 12 amino acids, and the others 
were designed as multimers (2, 3, & 4) of LBU1.  The WLBU peptides were derived from the 
LBU series by substituting Trp residues at the indicated positions. Not shown here are the peptide 
hydrophobic moments calculated according to Eisenberg. 
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antimicrobial potential of LLP1 demonstrate that the parent sequence is remarkably potent when 
compared with other host-derived antimicrobial peptides (396). Based on these studies, CAP 
derivatives can be engineered for enhanced potency and selectivity by increasing cationicity 
using Arg residues on the polar face and hydrophobicity using Val residues on the non-polar face 
(395).  This potency and selectivity can be further enhanced by increasing peptide length and by 
including Trp residues on the non-polar face as demonstrated by Vogel and colleagues (417).   
Similar to studies by McLaughlin and colleagues (251) and DeGrado  and colleagues 
(400), we reasoned that a de novo peptide presenting an optimized amphipathic α-helix with 
exclusively Arg residues on the hydrophilic face and Val residues on the hydrophobic face would 
demonstrate antimicrobial activity, as shown in this report.  An important question requiring 
attention was the optimal length of the peptide and the influence of Trp residues on the 
hydrophobic face.  In this study we describe the design and evaluation of de novo engineered 
peptides of varying length and Trp content for their in vitro activity and selectivity in a 
bacterial:host cell co-culture model.  The results demonstrate that it is possible to engineer an 
effective antimicrobial compound using a 24-residue peptide comprised only of Arg and Val  
residues.  Notably, increasing peptide length did not enhance antimicrobial potency in vitro, and 
inclusion of Trp residues on the hydrophobic face conferred increased selectivity in the 
bacterial:host cell co-culture model. 
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2.3. MATERIALS AND METHODS 
2.3.1. Peptide Synthesis 
The LBU and WLBU series (Figure 3), as well as the host-derived antimicrobial peptide 
LL37 (191, 406) were synthesized using standard Fmoc synthesis protocols as previously 
described (185).  Synthetic peptides were characterized and purified by reverse-phase HPLC on 
Vydac C18 or C4 columns (The Separations Group, Hesperia, CA), and the identity of each 
established by mass spectrometry (Electrospray Quatro II triple quadruple mass spectrometer, 
Micromass Inc., Manchester, UK). Peptide concentrations were determined using a quantitative 
ninhydrin assay as previously described (185). 
 
2.3.2. Bacterial Killing Assays 
Bacterial killing assays were conducted as previously described (396) using two 
prototypical pathogens, a clinical isolate of Pseudomonas aeruginosa (PA1244) and a 
laboratory-passaged strain of Staphylococcus aureus (396). Each of these isolates was confirmed 
to react identically to biochemical tests as American Type Culture derived strains of P. 
aeruginosa and S. aureus and was demonstrated to be susceptible to all antibiotics tested.  Also 
used for this study were two mucoid P. aeruginosa strains purchased from American Type 
Culture Collection and a series of clinical isolates identified by Children’s Hospital of Pittsburgh 
as P. aeruginosa exhibiting either a mucoid or a non-mucoid phenotype.   
To test for susceptibility of these index bacteria to the peptides described, bacterial 
suspensions (ca. 1 × 106 cfu/mL) in 10mM potassium phosphate buffer (PB) or phosphate buffer 
containing 150mM NaCl (PBS), pH 7.2, were incubated with two-fold dilutions of peptides for 
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30 min at 37°C.  Serial peptide dilutions were performed and plated on tryptic soy agar (TSA, 
Difco, Detroit, MI).  Surviving colonies were counted the next day to determine the minimum 
bactericidal concentration (MBC), defined as the molar concentration of peptide reducing the 
viable bacteria within a suspension by three orders of magnitude.  Values were expressed on a 
molar basis, with a lower MBC corresponding to increased peptide potency. The results were 
expressed as an average of MBC values obtained from three to five independent experiments.  
MBCs may be converted to micrograms per milliliter by dividing molecular mass (in g/mol) by 
1000 and then multiplying by the value in micromolar units.   
 
2.3.3. Circular Dichroism Analysis 
Circular dichroism (CD) was performed as previously described (185). Briefly, CD 
measurements were taken at 25ºC with an Aviv spectrometer (Aviv Instruments, Lakewood, NJ), 
over the range of 190-300 nm, and in PB or 30% trifluoroethanol (TFE) in PB. The average 
mean residue ellipticities ([Ө]/1000 x degree x cm2/dmol) for 8-10 scans per experimental trial 
were plotted against wavelengths (nm), and the program K2D (http://www.embl-
heidelberg.de/~andrade/k2d/) used to determine the percent helicity for each peptide in TFE (28).  
 
2.3.4. Selective Toxicity 
Primary human skin fibroblast (HSF) cells at passage 20 were propagated at 37ºC and in 
5% CO2 to over 80% confluence in Iscove’s Modified Dulbecco’s medium (IMDM) (Life 
Technologies, Grand Island, NY) containing 10% bovine fetal serum (BFS) and transferred (after 
trypsinization) to each well of a 96-well plate to a final count of 0.5 x 105 cells/well. After a 24-h 
incubation at 37ºC, the medium was aspirated and a 100µL suspension of P. aeruginosa 1244 
 33 
(~106 cells/ml in 50% serum-free IMDM) was added to each well. Using peptide concentrations 
from 0 to 10µM in 1x PBS, the bacterial/HSF media were further diluted to 25% IMDM. The co-
culture was then incubated at 37ºC for 1h. To determine bacterial survival, the co-culture 
medium was serially diluted after gentle pipetting to 1:1000 by transferring 20µL aliquots to 
another 96-well plate containing 180µL PBS per well. Each dilution was plated (100µL) on 
tryptic soy agar, incubated overnight at 37°C, and bacterial counts determined and expressed as 
colony forming units per mL (cfu/mL).   
Measurements of HSF cell viability were accomplished using a tetrazolium-based 
colorimetric assay (113, 204, 325). After washing twice with PBS, the co-culture medium was 
replaced with 100µL IMDM containing 10% FBS (vol/vol) and 0.5 mg/mL MTT Formazan 
(MTT) (Sigma, Lakehood, NJ).  The reaction mixtures were incubated at 37oC in 5% CO2 for 4h 
after which equal volumes of 0.1N HCl:isopropanol were added.  The percent viability was 
assessed by taking absorbances at 570nm using a Dynatech MR5000 (Germantown, MD). As 
controls, cells were treated with 25% IMDM (the test medium) in the presence or absence of 
bacteria, without the addition of peptide and with 100% lysis buffer [0.15M NaCl, 25mM 
Tris:HCl (pH 8.0), 1% (g/vol) deoxycholate and Triton X 100].  The experiments were 
performed in triplicate and viability data averaged. The final HSF toxicity values are expressed 
as mean percent toxicity for each test condition minus the percent toxicity in the presence of 
bacteria alone. 
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2.4. RESULTS 
Studies of the conservation of Arg and Val residues in the LLP1 sequences among 
diverse HIV1 isolates (396), coupled with engineering of the LLP1 sequence for greater potency 
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Figure 4.  Relationship between length and antibacterial activity 
Isolates of  P. aeruginosa (PA1244) were incubated with two-fold serially diluted peptides at 
37°C for 30 min. Bacterial survival at corresponding peptide concentrations was evaluated by 
broth dilution assays. The activity of the LBU series against P. aeruginosa in 10 mM phosphate 
buffer (PB) is both length- and dose-dependent, reaching almost an optimal level at 24 residues in 
length. 
 
 
 
(361, 395, 396, 407) and other studies related to host-derived antimicrobial peptides (251, 361, 
407),  led us to propose that effective de novo antimicrobial peptides could be synthesized solely 
from Arg and Val residues if positioned to optimize an amphipathic α-helix.   What was not clear 
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from previous studies was the minimum peptide length required for optimal antimicrobial 
activity.  In addition, since the membrane perturbation properties of Trp-rich antimicrobials (354, 
417) and fusogenic peptides (355) have been well described, we hypothesized that the inclusion 
of Trp residues on the hydrophobic face of an α -helix would increase antimicrobial potency. To 
address both of these issues, the series of peptides described in Figure 3 was designed based on 
the concept of a repeating lytic base unit of 12 residues.   
 
2.4.1. Antibacterial Potency of LBU Peptides of Increasing Length 
Using a standard broth dilution assay (396), the potency (i.e., antimicrobial activity on a per 
mole basis) of the LBU series and the host-derived human cathelicidin, LL37, was compared for 
killing P. aeruginosa in PB alone.  Figure 4 shows the dose-dependent bacterial survival in Log 
cfu/mL after peptide treatment.  There was a significant increase in activity from the 12-residue 
LBU1, which did not achieve an MBC at the concentrations tested, to the 24-residue LBU2, 
which demonstrated an MBC of 0.6µM (Table 1).  There was no appreciable increase in potency 
against P. aeruginosa for the 36-residue LBU3 and 48-residue LBU4 peptides. Interestingly, the 
LBU2 and LBU4 were more active than the host-derived human cathelicidin, demonstrating the 
increased potency of the de novo peptide component to a reference natural antimicrobial peptide.   
To define the minimum length for bacterial killing, a series of LBU peptides ranging 
from 12 to 24 residues were tested for their antimicrobial potency in PB and PBS against two 
index organisms, P. aeruginosa and S. aureus.  The results (Table 1) indicate that at a length of 
24 residues, optimal peptide activity (MBC 0.6µM) was achieved for P. aeruginosa in both PB 
and PBS, although some antimicrobial activity was observed with the 15- and 18-residue 
derivatives.   
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Table 1.  Influence of length and salinity on antibacterial activity a 
37                   1.2                     1.2 2.5                   >10 
12               >10                    >10 >10 >10
24                   0.6                     0.6 1.2                   >10 
36                   1.2                     0.6         0.6 1.2
48                   0.3                     0.3 0.3 0.3
12                   0.6                  >10                >10 >10 
24                   0.3                     0.3 0.3 0.3
36                   2.5                   0.6                    2.5                    0.3
48                   2.5                     0.6         2.5                    0.6
15                   1.2                   >10           >10 >10
18                   1.2                   >10           2.5                   >10
21                   0.6                   2.5                    1.2                >10
LL37
LBU1
LBU2
LBU3
LBU4
WLBU1
WLBU2
WLBU3
WLBU4
LBU1.3
LBU1.6
LBU1.9
PB                        PBSPB                      PBS
MBC (µM)
S. aureusP. aeruginosa PA1244Length 
(residues)
Peptides
 
 
aThe MBCs (peptide concentrations promoting 99.9% killing) of the LBU and WLBU series in PB 
and PB + 150 mM NaCl (PBS) were derived from the dose-dependent survival curves as previously 
described (26). (A) The human cathelicidin LL37 was used as a comparative host-derived peptide in 
these experiments. There was no significant change in antibacterial activity in peptides of 24-48 
residues in length, but the peptide LBU2 was salt sensitive against S. aureus. (B) The relationship 
between length and activity was further characterized using peptides of 12, 15, 18, 21, and 24 
residues. The results of these studies reveal that a minimum length of 15 residues is required for 
significant antibacterial activity. Average MBCs were obtained from 3-5 experimental trials.  
 
2.4.2. Influence of Trp residues on Antimicrobial Potency of the LBU peptides 
Trp is known to be a highly membrane active amino acid and is prevalent in many 
antimicrobial peptide sequences (417). The contribution of Trp residues to antimicrobial activity, 
when included on the hydrophobic side of the LBU peptide series, was investigated (Figure 3).  
As summarized in Table 1, a single Trp substitution in WLBU1 significantly increased anti-
pseudomonal potency when compared to the parent peptide LBU1 in PB, with an MBC of 
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0.6µM. The 24-residue WLBU2 derivative (three Trp residues in the hydrophobic face) 
displayed a slight increase in activity against P. aeruginosa in comparison to the LBU2, but it 
showed a significantly higher potency against S. aureus with an average MBC of 0.3µM in both 
PB and PBS. These findings suggest that the inclusion of Trp residues can render peptides less 
salt-sensitive and significantly more potent against S. aureus. As observed for the LBU series, in 
creased length did not result in increased potency for longer WLBU peptides, although WLBU3 
and WLBU4 peptides displayed similar resistance to NaCl for both index organisms. 
 
2.4.3. Relationship of Helicity in Membrane Mimetic Solvents to Antimicrobial Activity  
  The relationship between the propensity to form a helix and antibacterial activity was 
investigated using circular dichroism.  The LBU peptides described in Figure 3 were subjected to 
structural analysis in PB (mimicking an aqueous environment) and PB containing 30% TFE 
(mimicking a membrane environment).  Not surprisingly, no appreciable structure was observed 
for all peptides in PB (data not shown).  In contrast, the helical propensity in membrane mimetic 
solvents did correlate with bacterial killing (Figure 5).  In general, a percent helical value of 
greater than 80% correlated with the potency of bacterial killing (Table 2).   This finding is 
significant for the design of future de novo antimicrobial peptides, suggesting that helical content 
in a membrane environment should be preserved for maximal antimicrobial potency. 
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Figure 5.  Structure of de novo engineered antimicrobial peptides 
Circular dichroism analysis was performed on the LBU and the WLBU peptides under two 
conditions: (not shown) 10 mM phosphate buffer (PB) and 30% trifluoroethanol (TFE) as 
described previously. Mean residue ellipticities {[Ө]/1000 (degree x cm2)/dmol)} were plotted 
against wavelength, and the CD spectra shown here are representative of 3 independent 
experimental trials.   
 
2.4.4. Activity of WLBU2 against a Battery of P. Aeruginosa Isolates 
Based on the above experimental results, WLBU2 demonstrated the optimal peptide 
activity, i.e., it was the shortest, most potent peptide active against P. aeruginosa and S. aureus 
under physiological NaCl conditions.  To investigate whether the potent activity displayed by 
WLBU2 would be observed against other organisms in addition to the index strain, standard 
bacterial killing assays were performed in PBS using 16 clinical isolates of P. aeruginosa, six of 
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which were of a mucoid phenotype. The results are reported in Table 3 and demonstrate that 
WLBU2 maintains potent activity against all strains tested but also displayed a 2-16 fold higher 
(depending on the strain) bactericidal activity than that of LL37. 
 
Table 2.  Relationship between length and helical content a 
12                27
24                82
36                80
48                92
12                25
24                81
36                92
48 75
15                42
18                45
21                82
LBU1
LBU2
LBU3
LBU4
WLBU1
WLBU2
WLBU3
WLBU4
LBU1.3
LBU1.6
LBU1.9
% 
helicity
Length 
(residues)
Peptides
 
 
aTo evaluate the relationship between length and helical content, percent helicity was obtained 
from the CD data using the program K2d over the internet (www.embl-
heidelberg.de/~andrade/k2d/). Although length seems to correlate with helicity, there is little 
increase in helical content in peptides longer than 24 residues. These data, together with the 
results of the bacterial killing assays, reveal a similar correlation between helicity and 
antibacterial activity in phosphate buffer. The data tabulated are representative of 2-3 
experimental trials. 
 
2.4.5. Selective Toxicity 
Initial characterization of CAP cytotoxicity for human cells in our lab and others have been 
based on the human erythrocyte lysis assay (146, 265, 396, 401).  The results obtained by red 
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Table 3.  Antibacterial activity of WLBU2 is not strain specific a 
10.5PAO1
20.3ATCC33468*
50.3ATCC19142*
20.3PACO14
20.5PACO13*
20.5PACO12
20.5PACO11
20.3PACO10
10.3PACO9
10.3PACO8
20.5PACO7*
20.5PACO6
20.5PACO4
10.3PACO3*
20.5PACO1*
20.3PA1244
WLBU2             LL37
MBC (µM)P. aeruginosa Strains
*Mucoid type  
aTo investigate whether the potent activity displayed by WLBU2 was dependent on the specificity 
of the clinical strains, we performed standard bacterial killing assays (in PBS) using a panel of 16 
strains of P. aeruginosa, six of which were of mucoid phenotype. The peptide not only 
maintained its potent effects against all these strains, but also demonstrated a 4-13 fold higher 
bactericidal activity than that of LL37. The data tabulated are representative of 2 experimental 
trials. 
 
blood cell lysis, while informative, do not reflect the challenges of antimicrobial peptides that 
must be selectively toxic for bacterial cells over eukaryotic cells presented at the identical time 
and under identical conditions.  To more accurately assess the concept of selective toxicity, we 
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have developed a co-culture assay in which primary human skin fibroblasts (HSF) are infected 
with P. aeruginosa prior to peptide treatment. After 1h of exposure to peptide, these co-cultures 
were examined for bacterial killing and eukaryotic cell viability as described in the methods.  
LBU2 and WLBU2 were chosen for study in this assay because they were the minimal length 
peptides that demonstrated potent antimicrobial activity (Table 1) and low hemolytic activity 
(data not shown).   Figure 6 plots increasing concentrations of LBU2 (panel A) and WLBU2 
(panel B) as a function of bacterial killing (left axis) and eukaryotic cell toxicity (right axis).  The 
cytotoxic effects of LBU2 and WLBU2 on primary HSF cells were negligible at concentrations 
(<8µM and <2µM, respectively) that decrease bacterial load by 99.9%.  These data suggest the 
inclusion of Trp residues can significantly increase antimicrobial potency in a selective toxicity 
setting.  By comparison, the host-derived LL37 was moderately toxic to HSF cells (31% 
reduction at 10M), and a 99.9% reduction in P. aeruginosa was not attained at the maximum 
concentration tested (Figure 4, panel C).   The finding on the increased potency of the de novo 
designed antimicrobial peptides when compared to LL37 suggests that peptides of improved 
potency and selectivity can be generated.  
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Figure 6.  Selective toxicity of antimicrobial peptides in a co-culture system 
 
Primary human skin fibroblasts (HSFCCD-986sk) at passage 20 and over 80% confluence were 
infected with  P. aeruginosa in 50% Iscove’s modified Dulbecco’s medium (IMDM) in PBS with 
no bovine fetal serum. The co-culture was then treated for 1h with 2-fold dilutions of peptides as 
described in Materials and Methods. Bacterial survival was determined as in standard broth 
dilution assay, and HSF viability evaluated by MTT staining (a tetrazolium-based assay that 
measures the activity of mitochondrial redox enzymes). Controls included were 25% IMDM in 
PBS (0% cytotoxicity), 25% IMDM + bacteria (105-106 cells/ml), and 1x standard lysis buffer 
(100% cytotoxicity). The selected peptides LBU2 (A) and WLBU2 (B) displayed high 
antibacterial potency and selectivity in comparison to the host-derived peptide LL37 (13).  Data 
plotted are representative of three experimental trials. 
 
2.5. DISCUSSION 
In this study we demonstrated that antimicrobial peptides can be designed based on a 
cationic amphipathic motif using Arg residues on the cationic face and Val residues on the 
hydrophobic face.  Furthermore, we demonstrated that increased potency can be achieved by the 
inclusion of Trp residues on the hydrophobic face (predicted based upon the predominance of 
these residues in the indolicidins) (384).  The current study identifies LBU2 and WLBU2 as lead 
compounds for de novo antimicrobials based upon the minimal length of 24 residues for 
acheiving maximal antimicrobial potency.  The observation that these lead compounds are 
broadly active against our prototype gram-positive and -negative organisms, including mucoid 
and non-mucoid clinical isolates of P. aeruginosa, suggests that these peptides may be a template 
on which to base further derivatives.   
A de novo approach to peptide synthesis using natural amino acids is now predictable 
based on a comparison of the large number of host derived peptides (that exhibit a cationic 
amphipathic motif) described over the past two decades (69, 140). A review of the antimicrobial 
peptide literature raises the question of why a single sequence has not evolved as a predominant 
antimicrobial peptide functioning in the innate immunity of all vertebrate species.  It seems that 
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this cationic amphipathic motif has evolved in its place.  One possibility is that peptides with the 
same motif but with unique sequences behave differently against different bacterial pathogens in 
a variety of environments.     
McLaughlin and co-workers initiated the concept of multimeric peptide design from a 
unique sequence (251).  However, they limited their studies to peptides with a maximum length 
of 21 residues and thus did not allow for a complete appreciation of the effects of length on 
antimicrobial activity.  In addition, they used Lys as their predominant cationic residue.  In 
contrast, we exploited the membrane-active properties of Arg that have been documented in the 
literature (370, 417, 420).  We utilized Val on the hydrophobic face because of its predominance 
in the LLP1 derivatives that we have described previously (395, 396). Finally, substitution of the 
membrane-seeking amino acid Trp (355, 417) in the hydrophobic faces in the WLBU series also 
allowed us to appreciate its influence on antimicrobial activity and selectivity.  The possibility of 
using only three amino acids and synthesizing longer and more potent peptides in the form of a 
base unit is a novel aspect of these studies that affects the economic feasibility of peptide 
synthesis for large scale antibiotic production.   For example, the anti-HIV1 drug T20 is 
synthesized through the condensation of peptide fragments (216, 247, 404).   
We have shown that the activity of the LBU peptides was generally improved with 
increased chain length, with 24-residue peptides achieving optimal antibacterial selectivity. 
Although antibacterial activity correlated consistently with helicity for the LBU series, the 
length-potency correlation could be explained by better optimization of both the hydrophilic and 
hydrophobic faces with increasing length. However, hydrophobicity is the prime candidate in the 
observed increase in mammalian cytotoxicity.  LBU2, the most amphipathic (mean hydrophobic 
moment of 0.80) (177) and highly helical in this series, has the highest Arg-to-Val ratio (13/11), 
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thereby favoring strong initial interactions between the peptide and the highly electronegative 
LPS. This is supported by the observation that LBU3, with 36 residues and a lower hydrophobic 
moment (0.70), showed no net gain in activity in comparison to LBU2 against P. aeruginosa. 
  The Gram-negative P. aeruginosa has a double membrane, whereas S. aureus only a 
cytoplasmic membrane. An important question is why WLBU2 displays similar activities against 
both P. aeruginosa and S. aureus or why LBU2 is more potent against P. aeruginosa than 
against S. aureus. While higher activity against the single-membrane bacterium would be the 
apparent prediction, a better explaination takes into consideration the types of interactions as the 
most important antimicrobial determinant. The surface of P. aeruginosa is more electronegative 
than that of S. aureus. Therefore, stronger electrostatic interactions between LBU2 and the 
former would energetically favor the insertion of LBU2 into the P. aeruginosa outer membrane. 
Once LBU2 penetrates the outer membrane, it is possible that the barrier to the cytoplasmic 
membrane of this bacterium (e.g., thinner cell wall) is much weaker than that of the single 
membrane of S. aureus.  The Trp inclusion in the LBU2 derivative, WLBU2, enhanced the 
interaction between the peptide and the cytoplasmic membrane of S. aureus, possibly by stronger 
hydrophobic (in addition to electrostatic) interactions. By the same analysis, the peptide affinity 
would be even weaker for the surface of eukaryotic cells, which is much less electronegative 
than that of Gram-positive bacteria. An important concern is the transducing potential of these 
peptides due to the high proportion of Arg (>50%) in the primary sequence of LBU2 or WLBU2. 
The penetration of the eukaryotic cell membrane by the peptide could result in the destruction of 
the P. aeruginosa-like double membrane of the mitochodria and apoptosis. However, the 
concentration threshold for cytoplasmic membrane lysis or penetration is obviously higher for 
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eukaryotic than bacterial cells, which is supported by the observation that WLBU2 is toxic to 
both bacterial organisms at concentrations that do not affect the viability of the host cells. 
The peptide WLBU2, the most amphipathic of the WLBU series, was also the most 
potent in both PB and PBS and retained anti-pseudomonal selectivity presumably because of its 
high hydrophobic moment (µ = 0.83) (177). Moreover, the three Trp residues in the hydrophobic 
face rendered WLBU2 considerably active against S. aureus without significantly affecting its 
mammalian cytotoxicity. We are currently investigating the antibacterial activity of WLBU2 in 
human serum and its immunomodulatory effects on primary epithelial cells.  This information 
will be relevant to the potential in vivo efficacy of de novo engineered antimicrobial peptides. 
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3. CHAPTER 3: ACTIVITY OF THE DE NOVO ENGINEERED ANTIMICROBIAL 
PEPTIDE WLBU2 AGAINST PSEUDOMONAS AERUGINOSA IN HUMAN SERUM 
AND WHOLE BLOOD: IMPLICATIONS FOR SYSTEMIC APPLICATIONS 
3.1. Abstract 
Cationic amphipathic peptides have been extensively investigated as a potential source of 
new antimicrobials that can complement current antibiotic regimens in the face of emerging 
drug-resistant bacteria. However, the suppression of antimicrobial activity under certain 
biologically relevant conditions (e.g., serum and physiological salt concentrations) has hampered 
efforts to develop safe and effective antimicrobial peptides for clinical use. We have analyzed 
the activity and selectivity of the human peptide LL37 and the de novo engineered antimicrobial 
peptide WLBU2 in several biologically relevant conditions. The host-derived synthetic peptide 
LL37 displayed high activity against Pseudomonas aeruginosa, but demonstrated 
staphylococcal-specific sensitivity to NaCl concentrations varying from 50 to 300mM. 
Moreover, LL37 potency was variably suppressed in the presence of 1 to 6mM of Mg2+ and Ca2+ 
ions. In contrast, WLBU2 maintained its activity in NaCl and physiologic serum concentrations 
of Mg2+ and Ca2+. WLBU2 was able to kill P. aeruginosa (106 cfu/ml) in human serum, with an 
MBC <9µM. Conversely, LL37 was inactive in the presence of human serum. Kinetic assays of 
bacterial killing in serum revealed that WLBU2 achieved complete bacterial killing by 20min. 
Consistent with these results was the ability of WLBU2 (15-20µM) to eradicate bacteria from ex 
vivo samples of whole blood. The selectivity of WLBU2 was further demonstrated by its ability 
to specifically eliminate P. aeruginosa in co-culture with human monocytes or skin fibroblasts 
without detectable adverse effects to the host cells. Finally, WLBU2 displayed potent efficacy 
against  P. aeruginosa in an intraperitoneal infection model using female Swiss Webster mice. 
These results establish a potential application of WLBU2 in the treatment of bacterial sepsis.  
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3.2. Introduction 
The emergence of multiple drug resistance among bacterial pathogens has stimulated the 
search for new anti-infective agents that can complement current antibiotic regimens (133, 214, 
301, 312, 349, 368). Cationic amphipathic peptides (CAPs) have been extensively investigated as 
a potential source of these agents (212, 252, 312) and are a major class of antimicrobial peptides 
with different secondary structures (α-helix, β-sheets, loops, etc.) that provide neutrophils and 
epithelial surfaces of multicellular organisms with a rapid and efficient means of inactivating 
invading pathogens (27, 222, 224, 257, 340, 405, 410, 444). These ubiquitous peptides typically 
consist of 20 to 40 amino acid residues and are highly cationic. Most host-derived CAPs display 
broad activity against both gram positive and negative bacteria (27, 49, 52, 63, 107).  
The mechanisms of action of antimicrobial peptides, although not completely elucidated, 
have been widely studied. The interactions of CAPs with their microbial targets are thought to 
occur electrostatically and can be mediated by lipid molecules on bacterial surfaces (27, 192, 
239, 244). Numerous studies of CAP interactions with variably charged liposomes suggest that 
antimicrobial peptides selectively bind bacterial over eukaryotic cell membranes because of the 
negatively charged lipids found on the outer leaflets of the former (72, 153). The mechanisms of 
the antitumor and antiviral properties of CAPs are thought to be related to the presence of 
negatively charged phosphatidylserine molecules on the surfaces of tumor cells (118, 416) and 
sialic acid and heparan sulfate associated with viruses (25, 118, 148, 254). CAP antifungal (62, 
121) and immunomodulatory properties (3, 50, 199, 281) have also been reported. 
These peptides offer an appealing alternative as antimicrobial agents that can be used to 
combat multidrug resistance. Some bacteria display decreased susceptibility to several 
antimicrobial peptides by modifying their LPS or lipotheic acid molecules, leading to a decrease 
 49 
in net negative charge on the bacterial surface (94, 109). However, unlike the selection of 
resistance observed with current antibiotic treatments (333), the emergence of CAP-resistant 
phenotypes via multiple passages of bacterial strains is uncommon. In comparison to current 
antibacterial drugs, CAPs have the ability to kill bacteria very quickly (within 30 to 180sec) 
(396). Rapid killing allows little time for a particular genetic mutation in a bacterial cell to result 
in successful changes in the lipid bilayer, a process that likely requires modification of enzymatic 
pathways in addition to nucleotide or protein targets.  
Nevertheless, there are multiple obstacles to developing peptides of therapeutic potential. 
Despite the broad activity of host-derived peptides, their potency is often optimal only under 
specific conditions. For instance, several CAPs, although highly active in phosphate buffer, 
display a significant decrease in antibacterial potency in the presence of physiological 
concentrations of NaCl and divalent cations (93, 351, 391, 403, 437). Please note that the 
increased resistance to physiological NaCl concentration due to the inclusion of Trp residues in 
the LBU derivatives was discussed in the Chapter 2. In some cases (e. g., cystic fibrosis airway 
fluids), hypo-osmolar NaCl may be sufficient to significantly suppress antimicrobial function 
(209). Thus, the development of CAPs has been directed toward overcoming some of these 
challenges by either modifying host-derived peptides (188) or selecting specific amino acids for 
de novo design (252, 327, 330). Although several newly engineered CAPs demonstrate a 
significant degree of salt resistance (162, 163, 188, 330), current studies have not indicated that 
these peptides can overcome the obstacles encountered in physiological fluids and systems.  
Such limitations have shifted the focus upon developing CAPs as topical agents (152).  
We previously reported the de novo design of  modular CAPs comprised of multimers of 
12-residue lytic base unit (LBU) sequences of Val and Arg, with Trp substitutions (the LBU and 
 50 
WLBU series, respectively). In these peptides, the hydrophilic (Arg) and hydrophobic (Val and 
Trp) domains were maximally segregated (by 180°) and optimized as idealized amphipathic 
helical structures. The characterization of the activities of the LBU and WLBU peptide series 
against P. aeruginosa and Staphylococcus aureus led to the selection of WLBU2 (a 24-mer) as 
the shortest peptide with the highest antimicrobial potential, high helical propensity, and little 
toxicity to mammalian cells (162).  
The engineered peptide derivative WLBU2 (RRWVRRVRRWVRRVVRVVRRWVRR) 
is composed predominantly of Arg (13 residues) and Val (eight residues), with three Trp residues 
in the hydrophobic face separated from each other by at least seven amino acids. The residues in 
WLBU2 were arranged to form an idealized helical and amphipathic structure, with optimal 
charge and hydrophobic densities (162). By comparison, LL37 (LLGDFFRKSKEKIGKEF 
KRIVQRIKDFLRNLVPRTES) is an α-helical peptide with mainly Lys and Arg in the 
hydrophilic face and several different hydrophobic amino acid residues (Phe, Val, Ile, etc.) in the 
hydrophobic domain. LL37 has distinct cationic and hydrophobic domains with an amphipathic 
structure that is not as optimized as that of WLBU2.  
Based on these subtle but important structural differences, we sought to compare the 
potency of WLBU2 to that of LL37 in rigorous test conditions to demonstrate how certain 
limitations of host antimicrobial agents can be overcome using newly designed peptides with 
optimized amphipathic structures. To conclude these studies, the in vivo efficacy of WLBU2 was 
examined in a mouse model of P. aeruginosa bacteremia. The results of our investigations 
suggest that WLBU2, in contrast to LL37, is an antimicrobial agent that may have applications to 
systemic infections. 
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3.3. Materials and Methods 
3.3.1. Peptide Synthesis 
The peptides WLBU2 and LL37 were synthesized using standard FMOC synthesis 
protocols as previously described (396).  Synthetic peptides were characterized and purified by 
reverse-phase HPLC on Vydac C18 or C4 columns (The Separations Group, Hesperia, CA), and 
the identity of each established by mass spectrometry (Electrospray Quatro II triple quadruple 
mass spectrometer, Micromass Inc., Manchester, UK). Peptide concentrations were determined 
using a quantitative ninhydrin assay as previously described (396). A peptide sample of known 
concentration was used to evaluate several stocks of WLBU2 by spectrophotometric analysis, 
based on Trp absorbance at 280nm. By plotting different absorbances at 280 nm against peptide 
concentrations, a standard curve was generated from which concentrations of WLBU2 were 
deduced. 
 
3.3.2. Bacterial Killing Assays 
Bacterial killing assays were conducted as previously described (162, 396) using  the P. 
aeruginosa strain PA01 (ampr) provided by Dr. Barbara Iglewski (University of Rochester, NY). 
In selected studies, a methicillin resistant strain of S. aureus (MRSA) (obtained from Children’s 
Hospital of Pittsburgh Microbiology Laboratory) was used as a target bacterial strain. To test the 
susceptibility of these index bacteria to the peptides described, the standard NCCLS microbroth 
dilution assay had to be modified to compare the influence of NaCl, Mg2+, Ca2+, sera, or whole 
blood on the activity of WLBU2 and LL37.  The medium used was 10mM phosphate buffer, pH 
7.2, (PB) to which the aforementioned substances were added as described in each experiment.  
In all except the kinetic experiment, exposure time was held at 30 min.  Bacterial suspensions 
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(ca. 1×106 cfu/mL) in PB or containing NaCl, Mg2+, Ca2+, sera, or whole blood as described 
were incubated with two-fold dilutions of peptides for 30min at 37°C.  Following treatment, the 
bacterial samples were plated on tryptic soy agar (TSA) (Difco, Detroit, MI) to assay viable 
bacteria.  Surviving colonies were counted the following day to determine the minimum 
bactericidal concentration (MBC), defined as the molar concentration of peptide reducing the 
viable bacteria within a suspension by three orders of magnitude.  Results were expressed on a 
molar basis as an average of MBC values obtained from two to five independent experiments. 
This assay was also performed in the presence of heat-inactivated human serum (306) or plasma, 
ACES buffer (0.05mM ACES, 0.12mM NaCl, pH 7.34), or ACES-based CaCl2 or MgCl2 
(Sigma, St Louis, MO), as indicated. As a substitute for PB, ACES buffer was used to avoid the 
precipitation of calcium or magnesium phosphates. 
 
3.3.3. Kinetics of Bacterial Killing 
The procedure for bacterial killing assays was modified to determine the rate of bacterial 
killing by WLBU2 and LL37. P. aeruginosa strain PA01 (ca. 1×106 cfu/mL) was treated with 
15µM peptide in human serum (isolated from blood samples taken from healthy donors) and 
1µM in the presence of PBS. Aliquots of 20µL of the peptide-treated suspension were withdrawn 
at different times from 0 to 30 min at room temperature, serially diluted, and plated on TSA to 
determine bacterial counts. Average values for triplicates were expressed as log cfu/mL plotted 
against time (min). 
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3.3.4. Selective Toxicity in Co-culture Systems 
3.3.4.1. Selective Toxicity in Human Whole Blood 
Heparinized human blood from healthy donors (with the approval of the University of 
Pittsburgh Institutional Review Board) was inoculated with mid-log phase P. aeruginosa PA01 
cells (ca. 1×106 cfu/mL) and then treated with varying concentrations of peptide ranging from 0-
50µM to a total volume of 550µL. The reaction mixture was incubated at 37°C for 60min with 
gentle shaking. To determine viable bacterial count, each sample was serially diluted using 20µL 
as described previously. For parallel analysis of red blood cell (RBC) lysis, the remaining 
suspension was spun at 14000rpm (20,000 g) in an Eppendorf centrifuge model 5417C 
(Brinkmann Instruments, Westbury, NY) for 4min, and 50µL of the supernatant (hemoglobin 
fraction) diluted in 450µL distilled water. Similarly, 0-50µL untreated blood was diluted with 
water to a final volume of 500µL, and the supernatant (hemoglobin suspension) used to produce 
a standard curve of RBC lysis. The average absorbance values of the supernatants of all samples 
(200µL) were measured in duplicate in a plate reader at 570nm as a measure of hemoglobin 
released from lysed cells. Red blood cell lysis buffer (8.3g/L ammonium chloride in 0.01M Tris-
HCl, pH 7.5, Sigma, St. Louis, MO) was used as a control (50µL whole blood and 450µL 
buffer). Percent RBC lysis and bacterial survival were compared to determine the selective 
potential of the peptides. These experiments were verified by four independent trials. 
 
3.3.4.2. Co-culture of Human Cells with P. Aeruginosa 
To determine the selectivity of WLBU2 for bacteria versus human cells, the activities of 
WLBU2 and LL37 were assayed in a co-culture of human monocytes or primary human skin 
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fibroblasts (HSF) with P. aeruginosa. Peripheral blood monocytes were isolated from buffy 
coats obtained from sterile and heparinized human blood samples. Using histopaque gradient 
centrifugation (Sigma, St. Louis, MO), PBMC were isolated, and monocytes subsequently 
removed by adherence on 2% gelatin (Sigma, St. Louis, MO) plates. After isolation, the 
monocytes in RPMI were transferred to a 96-well plate (105 cells/well in RPMI or IMDM) and 
incubated at 37°C and 6% CO2 until a monolayer was formed. The medium was aspirated, and a 
100µL suspension of P. aeruginosa PA01 (2×106 cells/mL in 99% human serum) was added to 
each well. The bacterial suspensions over the eukaryotic cell monolayer were further diluted 
to106 cells/mL with equal volumes of peptide at various concentrations (0 to 100µM) in 99% 
human serum. The co-culture was then incubated at 37ºC for 30min. To determine bacterial 
survival, the co-culture medium was serially diluted (after gentle pipetting) up to 1:1000 by 
transferring 20µL aliquots to another 96-well plate containing 180µL PBS per well. Each 
dilution was plated (100µL) on tryptic soy agar (TSA) and incubated overnight at 37°C. 
Bacterial counts were then determined and expressed as a logarithm of colony forming units per 
mL (log cfu/mL).   
To further characterize the selectivity of WLBU2 with regard to P. aeruginosa and 
human cells, this co-culture assay was also performed using human skin fibroblasts (HSF) 
(passage 20) in Iscove’s Modified Dulbecco’s Medium (IMDM) (Invitrogen, Grand Island, NY) 
Measurement of host cell viability post-peptide treatment was accomplished using a 
tetrazolium-based colorimetric assay (237, 457). After two consecutive gentle washes with PBS, 
the cells were incubated in 100µL IMDM (HSF) or RPMI (monocytes) containing 10% FBS 
(vol/vol) and 0.5mg/mL MTT Formazan (MTT) (Sigma, Lakehood, NJ).  The reaction mixtures 
were incubated at 37oC in 5% CO2 for 4-6h after which equal volumes of 0.1N HCl:isopropanol 
 55 
were added to dissolve the resulting blue crystals.  The percent viability was assessed by taking 
absorbance measurements at 570nm using the Dynatech MR5000 96-well plate reader 
(Germantown, MD). For controls, cells were first treated with 100% serum (the test medium) in 
the presence or absence of bacteria, or with 100% lysis buffer [8.76g NaCl, 10g DOC, 1M Tris 
HCl (pH 8.0), and 10g Triton X 100, per liter of dH20] in the absence of bacteria.  The 
experiments were performed in triplicate, and viability data averaged. The final toxicity values 
were expressed as mean percent toxicity for each test condition minus any observed toxicity to 
the human cells by bacterial treatment alone.  
 
3.3.5. Host Toxicity and Proliferation Assays in the Absence of Bacteria 
To investigate the influence of WLBU2 on human cells in the absence of bacteria, we 
sought to determine whether long-term peptide treatment of human cells would adversely affect 
cell viability or functionality. Thus, freshly isolated human blood monocytes were treated with 
15µM WLBU2 or LL37 for 48h at 37°C and 6% CO2 in human serum. Cell viability in the 
presence or absence of peptide was evaluated by MTT staining as described previously. To 
characterize the influence of the peptides on lymphocytic proliferation, peripheral blood 
mononuclear cells (PBMC) were isolated and treated with 15µM peptide in RPMI-based 70% 
fetal bovine serum for 30min, at 37°C and 6% CO2. Subsequently, equal volumes of the 
mitogens, PMA (50ng/mL) and ionomycin (250ng/mL) in RPMI were added to each well. After 
3 days, 3H-thymidine (1µCi/well in 50µL RPMI) was added to the test and control (no peptide 
and/or unstimulated) wells. Following incubation for 16-18h, the cells were harvested onto a 
filtermat using a Tomtec cell harvester (Hamden, CT), and incorporation of 3H-thymidine 
detected in a Wallac Microbeta Liquid Scintillation Counter (Turku, Finland). To calculate 
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stimulation indices, radioactive counts per min (cpm) for mitogen-treated (stimulated) samples 
were divided by cpm for untreated samples (unstimulated). 
In vivo Toxicity  
Before evaluating the antibacterial efficacy of WLBU2 in vivo, it was essential to 
examine its toxic potential, which was performed via intravenous (IV) administration. Female 
Swiss Webster mice (Taconic, Germantown, NY) were injected IV with 0.1mL PBS and 3, 6, 12, 
or 16mg WLBU2 per kg body weight. Each dose was administered twice within 24h, and all 
mice (10/group) were monitored for signs of toxicity such as weight loss, piloerection, motility, 
histopathology, and survival. 
 
3.3.6. In Vivo Toxicity 
Before evaluating the antibacterial efficacy of WLBU2 in vivo, it was essential to 
examine its toxic potential, which was performed via intravenous (IV) administration. Female 
Swiss Webster mice (Taconic, Germantown, NY) were injected IV with 0.1mL PBS and 3, 6, 12, 
or 16mg WLBU2 per kg body weight. Each dose was administered twice within 24h, and all 
mice (10/group) were monitored for signs of toxicity such as weight loss, piloerection, motility, 
histopathology, and survival. 
 
3.3.7. Intraperitoneal Bacterial Inoculation Followed by Intravenous Antibacterial 
Therapy 
Mid-log phase bacteria (P. aeruginosa PA01 ampr), were prepared in sterile PBS to 
achieve the desired bacterial suspensions for intraperitoneal (IP) injections. Prior to examining 
the efficacy of WLBU2 in vivo, the minimum Pseudomonas lethal dose (PLD), the minimum 
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dose causing 100% mortality, was determined (1×107 cfu) and used in a 0.5 ml  volume to inject 
bacteria IP.  The animals were then randomized to receive IV isotonic sodium chloride solution 
(control group), or 3 mg/kg WLBU2 30 to 45min after bacterial challenge. The animals in each 
group, which included 14 mice (7/group for each of 2 independent trials), were returned to 
individual cages and subsequently monitored for 7-10d. The end points of the study were 
indicated either by 7-10d survival or by complete absence of motility and presence of 
hypothermia (Thermistor thermometer, Kent Scientific, Torrington, Connecticut) as signs of 
terminal illness or lethality.  
 
3.3.8. Evaluation of Treatment 
Quantitative blood cultures on carbenicillin TSA plates (200µg/ml) were performed to 
determine bacterial loads over the course of the infection. Blood samples were obtained from the 
tail vein by aseptic percutaneous puncture 0.5h to 36h after bacterial challenge and serially 
diluted. Then, a 0.1mL volume of each dilution was spread on carbenicillin TSA plates and 
incubated at 37°C overnight for enumeration of developed colonies. At the disease endpoint, 
animals were euthanized, and tissues weighed and homogenized using 70µm cell strainers 
(Becton Dickinson, Franklin Lakes, NJ) to determine bacterial cfu/g tissue. To compare fatality 
rates between different groups (treated and mock-treated), the Log-rank test was performed using 
GraphPad Prism version 3.00 for Windows, GraphPad Software, San Diego California USA, 
www.graphpad.com. Significance was accepted when P values were less than 0.05. 
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Table 4. Influence of sodium, magnesium, and calcium chloride on antibacterial activity a 
<1>53
<2>56
0.5>51
0.50.50CaCl2
<1>56
<0.5<2.51
3
0
300
150
50
0 0.50.5NaCl
WLBU2LL37
<0.5>5
<0.50.5Mg 
Cl2
0.51.2
0.250.5
0.50.5
MBC (µM)
Salt (mM)
 
aP. aeruginosa PAO1 was incubated with 2-fold serially diluted peptides at 37°C for 30 min. Bacterial 
survival at corresponding peptide concentrations was evaluated by broth dilution assays as described in 
Materials and Methods. Sodium chloride, even above physiological concentration, had negligible effects 
on the activities of LL37 and WLBU2 against P. aeruginosa. However, LL37 showed an Mg2+- and Ca2+-
dependent decrease in potency, while the activity of WLBU2 was slightly inhibited at 6mM divalent 
cations. The MBCs were derived from representative values of two-three independent experimental trials. 
MBC = minimal bactericidal concentration. 
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3.4. RESULTS 
3.4.1. Influence of Physiological Salt Concentrations on Antipseudomonal Activity 
As previously mentioned, the activity of host-derived antimicrobial peptides is often 
inhibited in the presence of physiological serum concentrations of sodium chloride and divalent 
cations (304, 403). For instance, we initially demonstrated that LL37 was inactive against S. 
aureus in PBS (162). However, the activity of the de novo engineered peptide WLBU2 was not 
altered under such conditions. To further examine the influence of salt on antibacterial activity, 
we treated P. aeruginosa with different peptide concentrations in varying NaCl conditions up to 
300mM. As indicated in Table 4, the peptides were highly toxic to P. aeruginosa in NaCl (at all 
concentrations), with MBC ranging from 0.5-1 µM (2.3-4.5µg/mL) for LL37 and ≤0.5µM 
(1.7µg/mL) for WLBU2. However, LL37 displayed a significant salt-dependent decrease in 
activity against MRSA, with an MBC greater than 2µM in as little as 50mM NaCl (data not 
shown). In contrast, the activity of WLBU2 against MRSA remained unchanged under varying 
NaCl conditions, with MBCs <0.5µM (data not shown). These results provide evidence that, 
unlike LL37, WLBU2 has the ability to resist broad changes in NaCl concentrations regardless 
of the test organisms (gram-negative P. aeruginosa or gram-positive MRSA).   
Divalent cations bridge lipopolysaccharides on bacterial surfaces, suggesting that they 
may serve as competitive inhibitors to CAPs. To investigate whether divalent cations can inhibit 
peptide activity, we determined the dose-dependent effects of Mg2+ and Ca2+ on peptide activity 
using 1, 3, and 6mM MgCl2 and CaCl2 in ACES buffer (normal physiological serum 
concentrations of Mg2+ and Ca2+ are in the range of 2 ± 0.5mM). The activity of LL37 was 
significantly inhibited in a dose-dependent manner, as MBCs were greater than 5µM at 3mM 
Mg2+ (Table 4). In contrast, WLBU2 activity was unaffected at concentrations as high as 3mM 
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Mg2+ (MBC <0.5). However, there was a small increase  in MBC (<1µM) at 6mM. The effects 
of Ca2+ on the activity of both peptides were slightly more apparent, with LL37 not reaching an            
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Figure 7.   Activity of WLBU2 in human serum 
 
To determine activity in human plasma, bacterial isolates of P. aeruginosa PAO1 (~106cells/ml) 
were incubated with 2 fold serially diluted peptides at 37°C for 30 min either in heat-inactivated 
human plasma or serum. Bacterial survival at corresponding peptide concentrations was evaluated 
by broth dilution assays as previously described. WLBU2 was able to sterilize the bacterial 
suspension at 12.5 µM, while LL37 demonstrated no significant activity even at 100 µM (not 
shown). Results of activity in serum and plasma were identical. The graphs were derived from 
average values of four independently generated and almost identical triplicate sets of data. MBC = 
minimal bactericidal concentration.  
 
MBC within 0-5µM even in as low as 1mM CaCl2. WLBU2 was four-fold less active in calcium 
concentrations varying from 1mM (MBC = 0.5µM), to 6mM (MBC <2µM) (Table 4). Notably, 
calcium ions only had a minor inhibitory effect on WLBU2 (MBC <1µM) within physiological 
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concentration range (1.5-2mM). These results suggest that WLBU2 has been successfully 
engineered to be unaffected by broad variations in NaCl and divalent cation concentrations found 
to be challenging for host-derived peptides. 
 
3.4.2. Antibacterial Activity and Selectivity in Human Serum 
The inactivation of CAPs in human serum has hindered efforts to develop antimicrobial 
peptides for systemic use (152, 246). As a consequence, less challenging conditions (e.g., 
phosphate buffer) are commonly used to examine antibacterial activity and host toxicity. 
Moreover, the characterization of antimicrobial selectivity has been based on the exposure of 
mammalian cells to peptides in the absence of microbial pathogens in media or buffer (e.g., red 
blood cell lysis assay in PBS) (396). To evaluate antibacterial selectivity more appropriately, we 
have developed a comprehensive series of experiments in which both bacteria and host cells are 
mixed prior to the addition of peptide. This assay was previously described in a study in which 
HSF and P. aeruginosa PA1244 were combined and then treated with peptide in PBS-based 
IMDM (162). Although this assay provides important information about the selective target of a 
peptide, it remains unclear whether similar results would be expected under biological 
conditions.    
To investigate the potential of WLBU2 for systemic applications, we initially examined 
the influence of human serum on its antibacterial activity and compared it with that of LL37. 
Thus, P. aeruginosa suspensions were treated with increasing peptide concentrations in the 
presence of human serum (98%). As indicated in Figure 7, LL37 displayed no significant activity 
even at concentrations up to 100µM (data not shown). By contrast, WLBU2 was highly active 
against P. aeruginosa, with no bacterial survival observed at 12.5µM (MBC of <9µM).  Because 
peptide clearance may have a profound impact on activity in vivo, we compared the rates of  
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bacterial killing in human serum and in PBS (Figure 8). The results of this experiment indicate 
that the peptide WLBU2 requires at most 20min to kill about 1×106 cfu/ml of P. aeruginosa at 
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Figure 8.  Kinetics of bacterial killing 
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P. aeruginosa PAO1 was treated with 15 µM peptide in human serum (A) and 1µM in PBS (B). 
Bacterial survival was monitored over time (up to 30 min) and determined as described in 
Materials and Methods. The results reveal that a minimum period of 20 min is required for 
complete bacterial killing in about 98% human serum. The peptide LL37 was inactive under this 
condition as expected. However, both LL37 and WLBU2 achieved complete killing within the 
first 5 min of treatment in PBS. Data plotted are representative average values for one triplicate 
set from 3 independent experiments.   
 
15µM in approximately 98% human serum. As expected, LL37 did not show significant activity 
over time in human serum. Not surprisingly, both peptides sterilized a similar bacterial 
suspension of P. aeruginosa PA01 (1×106 cfu/ml) in PBS at a concentration of 1µM in less than 
5min. These data suggest that WLBU2 should be further investigated for systemic use. 
The higher MBC of WLBU2 in human serum raised a concern for potential toxic effects 
on mammalian cells. Moreover, it remained unclear whether the complete cellular composition 
of whole blood would affect antibacterial potency. To address these two issues, we examined the 
antibacterial selectivity of WLBU2 in human whole blood. In this system, a bacteremic condition 
was established ex vivo with P. aeruginosa PA01 (1×106 cfu/ml) prior to addition of peptide. 
Bacterial survival was determined by serial dilution assay, and red blood cell lysis was deduced 
from a standard curve generated by spectrophotometric analysis of water-treated blood. As 
predicted, LL37 did not show any antibacterial activity against P. aeruginosa (data not shown). 
Conversely, WLBU2 demonstrated the ability to “sterilize” the Pseudomonas-inoculated blood 
at 15-20µM peptide (Figure 9), consistent with its activity in human serum. In addition, there 
was no detectable toxicity to the erythrocytes at all test concentrations (up to 50µM). These 
results further underscore the enhanced potency of WLBU2 over the host peptide LL37 and may 
serve as a preliminary indicator of the antibacterial potential of WLBU2 in vivo.  
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Because the blood cell lysis assay did not reveal any specific information about the fate 
of the leukocytes in the ex vivo bacteremic model, the cytotoxic effect of the peptide on human 
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Figure 9.  Peptide efficacy in an ex vivo bacteremic model 
 
Human whole blood was inoculated with P. aeruginosa PAO1 (~106cells/ml) and treated with 
peptide at various concentrations for 45 min at 37°C. Bacterial count was determined by standard 
bacterial dilution assay and blood cell lysis by spectrophotometric analysis of hemoglobin 
release. The erythrolytic effect of red blood cell lysis buffer was comparable to that of water, 
which was used to generate the standard curve (not shown) in this assay, as described in materials 
and Methods. The peptide WLBU2 was remarkably selective against the bacterial cells, with no 
detectable lytic effects on the blood cells. The graph was derived from average values of four 
independently generated and almost identical triplicate sets of data. MBC = minimal bactericidal 
concentration. 
 
blood monocytes was investigated.  To accomplish this, cultures of freshly isolated peripheral 
blood monocytes were inoculated with P. aeruginosa in heat-inactivated human plasma or serum 
(306). Subsequently, the co-culture was treated with peptides as described in Figure 4. Using a 
tetrazolium-based staining method (MTT), the level of toxicity to the monocytes was 
determined. WLBU2 did not affect the viability of the monocytes (0% cytotoxicity).  
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Figure 10. WLBU2 selectively targeted P. aeruginosa in a co-culture model in human 
plasma 
 
Approximately 105 Human monocytes (A) or primary human skin fibroblasts (HSFCCD-986sk) 
at passage 20 (B) were inoculated with P. aeruginosa in 98% heat-inactivated human serum. The 
co-culture was then incubated for 60 min with 2-fold dilutions of peptides as described in 
Materials and Methods. Bacterial survival was determined as in standard broth dilution assay and 
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the percent viability of the human PBMC or HSF evaluated by MTT staining. The peptide 
WLBU2 displayed high antibacterial selectivity in comparison to the host-derived peptide LL37 
(not shown).  Data plotted are representative averages from 3 independent experimental trials.  
MBC = minimal bactericidal concentration. 
 
Consistent with antibacterial activity in human blood, bacterial killing was optimal at 15µM 
peptide for both peripheral blood monocytes (Figure 4A) and primary HSF (Figure 4B). Again, 
LL37 was inactive under these conditions (data not shown). Taken together, these results 
underscore the high antibacterial selectivity of WLBU2 and identify it as a potentially effective 
and safe antimicrobial agent. 
 
3.4.3. Effects of WLBU2 on Host Cells in the Absence of Bacteria 
The results of the previous experiments demonstrate the effects of WLBU2 on human 
cells after only a short-term treatment. Furthermore, the influence of WLBU2 on the 
functionality of these cells remains unclear.  To address these issues, the influence of WLBU2 on 
the viability of human PBMCs after exposure for 48h in human serum using MTT staining was 
determined. PBMC remained 100% viable in MTT assay (data not shown). Despite the evidence 
shown here in support for the safety of WLBU2 in a host environment, it could still be argued 
that, although nontoxic to mammalian cells in serum, WLBU2 could affect their functionality. 
To address this issue, we attempted to examine the influence of WLBU2 on lymphocytic 
proliferation. Thus, human blood lymphocytes were treated with 15µM peptide for 30min prior 
to the addition of PMA and ionomycin to determine the proliferation level by H3-thymidine 
incorporation within 4d of stimulation (data not shown).  The results show that lymphocyte 
proliferation either remained unchanged or increased by up to 15% for both LL37- and WLBU2-
treated samples compared with untreated samples. On the whole, this study demonstrates that it 
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is possible to design antimicrobial peptides with optimized amphipathic helical structures for 
overcoming the challenges of physiological salt concentrations and biological fluids. 
 
3.4.4. In Vivo Toxicity and Antipseudomonal Efficacy in an IP Infection Model 
Both in vitro and ex vivo observations suggest the possible application of WLBU2 in the 
treatment of bacteremia. Thus, it was deemed logical to examine the potential therapeutic 
application of WLBU2 in a septicemic animal model of P. aeruginosa infection. Initially, we 
characterized the lethal potential of the peptide within a range of concentrations to determine the 
maximum tolerated dose (MTD). For these experiments, groups of 10 mice (25g each) were 
given two equal doses of WLBU2 IV varying from 3 to 16mg/kg body weight within 24h (Figure 
5A). The peptide displayed no lethality or apparent toxic effect at up to 12mg per kg body weight 
in comparison with PBS-injected mice (not shown), but  the mice  receiving the highest peptide 
dose (16mg/kg mouse) died within 30min post-injection. no lethality, however, was observed in 
the other groups. Thus, the MTD for IV administration, the highest IV dose of WLBU2 that led 
to no obvious toxicity to the mice, was 12mg/kg. We are currently in the process of identifying 
the physiological basis for this toxicity. 
Based on the toxicity profile of WLBU2, a bacteremic mouse model was developed to 
test the therapeutic potential of the peptide using female Swiss Webster mice. Initially, the 
minimum P. aeruginosa lethal dose (PLD) was evaluated by IP injections. It was determined that 
mice (~25g each) subjected to IP administration of 107 cfu (PLD) became terminally ill and 
required euthanasia within 36h (data not shown). IP-injected mice (107 cfu P. aeruginosa) 
treated IV with isotonic NaCl (PBS) became bacteremic after 2h post-injection (approximately 
1000 cfu/mL blood). Bacterial loads increased to 1-10 billion cfu/mL of blood at the disease 
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endpoint (data not shown). Consistent with this finding was the observed dissemination 
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Figure 11.  WLBU2 in vivo efficacy against P. aeruginosa 
 
To characterize the in vivo efficacy of WLBU2, we first determined the maximum tolerated dose 
(MTD) IV by injecting female Swiss Webster mice with PBS or 3 -16mg WLBU2 per kg body 
weight IV. The animals were then followed for a minimum of 7 days for survival. Mice treated 
IV with 16mg WLBU2 per kg body weight died within 30min post-treatment. As shown in the 
Kaplan-Meier survival curve, the IV MTD is 12mg WLBU2 per kg body weight (A). Therefore, 
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the LD50 is between 12 and 16mg/kg. (B) The therapeutic potential of WLBU2 was determined 
by injecting mice IP with PAO1 (1.0-1.5 x 107 cfu). The animals were treated 30-45min post-
injection with PBS, and bacterial load determined over time by blood culture on carbenicillin 
(200µg/mL) tryptic soy agar plates. The establishment of bacteremia began in about 2-3h (data 
not shown) and progressed to septicemia and fatality within 36h. In contrast, when Pseudomonas-
infected mice were treated IV with 3 mg of WLBU2 per kg body weight 30-45min after the 
administration of the minimum PLD, not a single case of bacteremia and fatality was observed. A 
log rank test reveals a P value of less than 0.0001. 
 
of bacteria to the internal organs (liver, lungs, kidney, and spleen), with bacterial loads varying 
from 108-109 cfu per gram of tissue during terminal illness (absence of motility and 
hypothermia). Identically inoculated mice injected IV with 3mg WLBU2 per kg mouse 30-
45min after bacterial injections showed no signs of disease (normal motility, no piloerection, 
etc.). Moreover, no bacteria were recovered from the blood or the internal organs (liver, kidney, 
lungs and spleen) after 7-10d post-treatment (data not shown). Figure 5B illustrates a Kaplan-
Meier survival analysis of the difference between mice treated IV with PBS and mice treated IV 
with WLBU2 30-45min after IP injection of bacteria. No lethality was observed in WLBU2-
treated in comparison to mock-treated mice. It is concluded from this model that WLBU2 
demonstrated high efficacy against P. aeruginosa PA01 in vivo when systemically administered. 
  
3.5. DISCUSSION 
In this study, the activity of a reference natural antimicrobial peptide (LL37) is compared 
with that of a de novo peptide (WLBU2) under biologically relevant conditions proven to be 
challenging to many of the most commonly studied antimicrobial peptides (152, 209). As shown 
in this study, LL37 displayed no saline sensitivity against P. aeruginosa, but its activity was 
variably suppressed in the presence of Mg2+ and Ca2+ and human serum. In contrast, WLBU2 
was resistant to physiological concentrations of NaCl, MgCl2, and CaCl2. An important 
observation was the complete killing of P. aeruginosa by WLBU2 in human serum and whole 
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blood, without detectable adverse effects to human leukocytes, erythrocytes, and primary skin 
fibroblasts at concentrations five-fold above the MBC. However, the most critical finding was 
the antipseudomonal efficacy of WLBU2 in IP-infected mice. 
Studies of natural peptides indicate that NaCl and divalent cations (even at 
subphysiologic levels) may affect CAP activity (209).  In this study, LL37 sensitivity to NaCl for 
MRSA indicates that salt resistance is sometimes dependent on the test organism. Conversely, 
the highly cationic peptide WLBU2, a derivative of the de novo 24-mer sequence (LBU2), was 
shown to be highly potent against both P. aeruginosa and MRSA in similar NaCl concentrations. 
Based on the fact that this staphylococcal-specific salt sensitivity (displayed by LL37) was 
previously observed for the parent peptide LBU2 (162), it is evident that the strategic 
substitution of 3 Trp residues in the peptide hydrophobic face is likely to be responsible for the 
observed salt resistance against S. aureus. In support for this observation, several studies indicate 
that Trp may be an important determinant of antimicrobial activity (227, 228). For instance, a 
single substitution of Phe for Trp in lactoferricin considerably decreases its antimicrobial 
potency (416). In an attempt to examine the underlying mechanism of salt resistance, Park et. al 
demonstrated that salt resistance can be enhanced by increasing helical stability (327). As helical 
conformation is normally induced by peptide interaction with the bacterial surface, increasing the 
affinity of a peptide for the lipid bilayer should enhance its propensity to form a α-helix. In a 
saline environment, the hydrophobic and bulky rings of the Trp residues (by virtue of its 
membrane seeking property) are likely to enhance the affinity of WLBU2 for the bacterial 
membrane, thereby leading to a greater stability of the helical structure. However, raising the 
concentrations of Mg2+ and Ca2+ beyond serum physiologic levels had a minor inhibitory effect 
on the activity of WLBU2. This finding suggests that there is an optimal salt concentration (in 
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this case, twice the physiologic concentrations) beyond which the helical stability may be 
affected. One explanation could be that the divalent cations (at high concentrations) may more 
effectively compete with the peptide for the negatively charged bacterial surface. Nevertheless, 
an important lesson is that CAPs can be designed to overcome salt sensitivity using Trp 
substitutions. Further, the property of salt resistance displayed by WLBU2 may be particularly 
critical to treatment of infections in diseases that may disturb the normal salt homeostasis in 
certain human tissues (e. g., cystic fibrosis airway) (209).     
The recognition that CAP activity is usually suppressed in serum has restricted the 
development of antimicrobial peptides mainly to topical or local applications (e.g., skin, 
respiratory tract infections) (209, 246, 327). As described in this report, standard bacterial killing 
assays revealed that LL37 was totally inactivated in human serum, suggesting that, like most 
widely studied host-derived peptides, LL37 may not have evolved to fight systemic infections. In 
contrast, WLBU2 was not only highly potent against P. aeruginosa in human serum but also 
achieved complete killing by 20min, a potential advantage against rapid peptide degradation in a 
complete host environment. In human serum, the equilibrium between free and protein-bound 
peptide molecules could explain why bacterial killing is slower in comparison with killing in 
PBS. As more free molecules become associated with their bacterial target, the equilibrium 
would shift toward the progressive release of more peptide molecules, thus leading to effective 
but slower bacterial killing in human serum. 
Once WLBU2 was proven effective in serum, it was deemed logical to investigate 
whether it would be as potent in human blood (in the context of biological plus host cell 
environments). The efficacy of WLBU2 in the bacteremic model implies that it overcame the 
potential inhibitory effects of physiological serum salt concentrations, including divalent cations. 
 72 
In fact, it is more likely that serum proteins such as albumin or apolipoproteins (381) are 
responsible for the lower activity (in comparison with PBS) in human serum and whole blood. 
Notably, the antibacterial activity of WLBU2 was unaltered when blood samples derived from 
donors with hyperlipidemic disorders (milky blood or serum) were used (data not shown). 
Another important finding was the slightly lower (20-30%) antibacterial activity in co-culture 
assays in comparison to bacterial killing alone in human serum. This minor difference in activity 
might be due to interactions of the host cells (erythrocytes and leukocytes) with the peptide. The 
immunomodulatory properties of some host-derived CAPs have been demonstrated (358). 
Similarly, WLBU2 may have other effects on host cells, particularly on leukocytes, which is 
worthy of further investigation. These results provide new information that is critical to the 
characterization of the therapeutic potential of WLBU2 for systemic applications. 
In light of all this evidence for the antibacterial efficacy of WLBU2 in vitro, it was 
important to know whether there was a chance this peptide could display any toxicity to 
mammalian cells after a short- or long-term exposure. Consistent with the bacteremic model, the 
MTT staining assays in human serum demonstrated that, given both bacterial and host cell 
targets, the peptide could discriminate against the bacterial cells while sparing the leukocytes and 
HSF cells. Likewise, a long-term treatment of these cells in the absence of bacteria had no effects 
on their viability. Moreover, the lymphocyte proliferation assay ruled out the concern that the 
peptide might specifically and adversely affect host cell functionality.  
One of the greatest obstacles in the field of antimicrobial peptides is the transition from 
test tube to animal models because of the sensitivity of CAPs to biological environments, as 
demonstrated in this study.  Due to these limitations, antimicrobial properties of  CAPs fall short 
of supporting their clinical use, with a just few exceptions (e.g., the polymyxins) (65, 339) . 
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The in vivo toxicity and in vivo efficacy of WLBU2 were also characterized using an IP 
model of P. aeruginosa bacteremia. The results indicated that WLBU2 was nontoxic at up to 
four times the effective therapeutic dose when administered systemically. Initially, WLBU2 was 
able to rescue a group of 14 mice from the progression of a P. aeruginosa infection. The 
reproducibility of these results provides convincing evidence for the systemic efficacy of 
WLBU2 against P. aeruginosa. An interesting feature of this IP infection model is the successful 
induction of Pseudomonas bacteremia without the need for an immunosuppressive drug (234, 
312). This important aspect of the mouse model will render possible the characterization of the 
immune modulatory properties of WLBU2 in vivo either on its own or in the context of a P. 
aeruginosa infection in a fully immunocompetent host. 
  In conclusion, we have demonstrated that a de novo antimicrobial peptide was able to 
overcome the challenges of physiological serum concentrations of NaCl, Mg2+, and Ca2+, while 
the synthetic form of the human peptide LL37 displayed a high sensitivity to NaCl and divalent 
cations.  In addition, LL37 activity was completely suppressed in human serum. In contrast, 
WLBU2 displayed high efficacy in human serum and the ability to eradicate a bacteremic 
condition ex vivo. Furthermore, there were no observed adverse effects on mammalian cells in 
terms of both cytotoxicity and functionality of blood lymphocytes. Finally, the in vivo efficacy of 
WLBU2 was demonstrated in an IP model of P. aeruginosa infection. These results, while 
promising, underscore the need for comparative studies of WLBU2 and standard 
antipseudomonal therapeutics (e.g., colistin, tobramycin) prior to its further consideration for 
clinical trials. Such studies should include, but not be limited to investigating dose-dependent 
response to bacteremia treatments in an IV infection model, peptide pharmacokinetics, 
immunogenicity, and influence on cytokine levels within or outside of the setting of an infection.  
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4. CHAPTER 4: DE NOVO-DERIVED CATIONIC ANTIMICROBIAL PEPTIDE 
ACTIVITY IN A MURINE MODEL OF P. AERUGINOSA BACTEREMIA 
 
4.1. Abstract 
Cationic antimicrobial peptides (CAPs) are a very diverse group of agents that 
demonstrate broad activity against Gram-positive and -negative bacteria. Because of the 
emergence of drug-resistant bacteria, CAPs have been extensively investigated as a potential 
source of new antimicrobials with novel mechanisms of action that may complement current 
antibiotic regimens. A major challenge to successful development of CAPs for clinical use is the 
suppression of antimicrobial activity under biological fluids (e.g., blood). We have previously 
analyzed the activity and selectivity of the de novo-derived antimicrobial peptide WLBU2 in 
several biologically relevant conditions. Recently, we demonstrated potent activity of WLBU2 in 
an intraperitoneal mouse model of Pseudomonas aeruginosa infection. In this study, we first 
evaluated the influence of WLBU2 on inflammatory cytokines to further characterize the toxic 
property of the peptide. The data indicate that WLBU2 had no effect on the levels of most 
cytokines, except for a minor stimulatory effect on IL1-β and TNF-α, the most potent 
inflammatory cytokines. We then characterized the in vivo efficacy of this peptide in an 
intravenous infection model. WLBU2 (3 to 4mg/kg) not only protected mice prophylactically, 
but was highly therapeutic when administered IV to P. aeruginosa-infected animals, with 
complete elimination of the bacteria from the blood and other tissues. These results, together 
with our previous data on the toxic potential and efficacy of WLBU2 in the IP infection model, 
provide strong evidence for a potential application of this peptide in the treatment of septicemia.  
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4.2. Introduction 
Despite the development of safe and potent antibiotics, bacterial diseases remain a 
worldwide health crisis. A serious concern is the emergence of multiple drug resistance (117, 
130, 137, 211, 223, 341). For instance, Pseudomonas aeruginosa is a gram negative bacterium 
known to cause disease in immunocompromised patients. Although opportunistic, P. aeruginosa 
poses a serious burden to the clinical management of infectious diseases because of its ubiquity, 
frequency of transmission in hospitalized patients, and high propensity to become resistant to 
multiple antibiotics. P. aeruginosa can cause severe diseases in patients with cystic fibrosis, 
burns, ventilator-associated pneumonia, and septic infections (53, 126, 127, 144, 169, 253, 350, 
392). Therefore, there is a critical need to develop more effective antimicrobials with novel 
bactericidal mechanisms to circumvent the obstacle of multiple drug resistance. 
A potential source of novel therapeutics are antimicrobial peptides referred to as cationic 
amphipathic peptides or CAPs (360, 442-444). The diversity of the primary sequences of these 
peptides and the conservation of amphipathicity in the native (α-helix, β-sheets, loops, etc.) 
structure suggest an essential role of the amphipathic property in antibacterial activity. Based on 
this amphipathic motif and amino acid compositions, CAPs generally demonstrate broad 
environment-dependent activity against Gram-positive and -negative bacteria (244, 360). Stored 
in phagocytic granules and secreted by epithelial cells in response to the presence of microbial 
organisms, host antimicrobial peptides play an essential role in innate immunity by providing an 
important mechanism for rapid and efficient clearance of invading pathogens (79, 80, 360). 
Some CAPs display modulation of cytokine levels and the adaptive immune response (360). 
Two critical issues on the functioning of CAPs are the suppression of activity in 
biological fluids (e.g., blood or blood-derived matrices) and the environment-dependent host 
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toxicity of many antimicrobial peptides. Numerous studies have been conducted to address these 
two issues by adopting two approaches. One is to modify natural peptides to improve their 
potency, and the other to design CAPs de novo based on structure-function specificity (162, 186, 
252, 286, 309, 400). It was previously shown that it was possible to achieve optimal potency in 
phosphate buffered isotonic NaCl by designing a 24-mer amphipathic peptide (WLBU2) with 
Arg on the hydrophilic face and mainly Val and 3 Trp residues in the hydrophobic face (162). 
More recently, we demonstrated that WLBU2 was highly active against P. aeruginosa in human 
serum and whole blood. To characterize the selective property of WLBU2 under these 
conditions, a competition assay was developed, which consists of bacteria and human cells 
simultaneously presented to the peptide under the aforementioned conditions. The results of 
these studies indicated that WLBU2 was nontoxic to red and white blood cells with a therapeutic 
window of >30µM. What remained unclear from these investigations was the potential in vivo 
efficacy of WLBU2 against P. aeruginosa.  
We hypothesized that the systemic administration of this peptide would prevent the 
progression of P. aeruginosa infections in experimental mouse models. This hypothesis was 
partially addressed in a previous report in which we described the efficacy of WLBU2 against P. 
aeruginosa in an intraperitoneal (IP) mouse model. In the current study the prophylactic, 
therapeutic, and cytokine modulatory properties of this peptide were investigated in an 
intravenous (IV) model of P. aeruginosa infection. It was found that WLBU2 was only weakly 
stimulatory to inflammatory cytokines, and that systemic administrations of WLBU2 increased 
survival of P. aeruginosa-infected mice by preventing the progression of the bacterial disease.  
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4.3. Materials and Methods 
4.3.1. Organisms 
The laboratory pathogen Pseudomonas aeruginosa PAO1 was used as described 
previously. The mouse of choice was the female Swiss Webster mouse (25-30g) strain, which 
was purchased from Taconic (Germantown, New York) because it was demonstrated that this 
strain can be susceptible to P. aeruginosa bacteremia without the use of an immunosuppressant. 
All animals were maintained and procedures performed according to protocol approved by the 
Institutional Animal Care & Use Committee (IACUC animal protocol number 0402610A-1) of 
the University of Pittsburgh, Pittsburgh, PA. All mice were housed in individual cages under 
constant temperature (22°C) and humidity using a 12-hr light/dark cycle. 
 
4.3.2. Peptide Synthesis 
The engineered peptide derivative WLBU2 (RRWVRRVRRWVRRVVRVVRRWVRR) 
was synthesized using standard FMOC synthesis protocols as previously described (394, 396).  
The synthetic peptide was characterized and purified by reverse-phase HPLC on Vydac C18 or 
C4 columns (The Separations Group, Hesperia, CA), and the identity of each established by 
mass spectrometry (Electrospray Quatro II triple quadruple mass spectrometer, Micromass Inc., 
Manchester, UK). Peptide concentrations were determined using a quantitative ninhydrin assay 
as previously described. A peptide sample of known concentration was used to evaluate several 
stocks of WLBU2 by spectrophotometric analysis, based on Trp absorbance at 280nm. 
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4.3.3. Evaluation of Inflammatory Responses 
To evaluate the influence of WLBU2 on inflammatory cytokine levels, mice were treated 
IV with WLBU2 (1 and 3 mg/kg), heat-killed bacteria (108cfu), or PBS. Blood was collected at 
3h and 5h, and sera isolated for quantification of an extensive panel of cytokines (IL1-β, TNF-α, 
Rantes, MIP-1α, etc.) using the Bio-Plex protein array system (Bio-Rad, Hercules, Calif.) 
according to the manufacturer's instructions. The Bio-Plex Manager version 3.0 software (Bio-
Rad) was used to determine the concentration (picograms per mL) of each cytokine or 
chemokine. Data are expressed as fold increase by dividing the cytokine concentration for each 
test sample to that of the control (PBS-treated mice).  
 
4.3.4. Intravenous Bacterial Inoculation Followed by Intravenous Antibacterial Therapy 
Suspensions of mid-log phase bacteria were centrifuged at 2000 × g for 10 min using the 
Adams Dynac I centrifuge (Becton Dickinson, Franklin Lakes, NJ). Supernatants were 
discarded, and the bacteria resuspended and diluted in sterile PBS to achieve a concentration of 
approximately 2-4 × 108 colony-forming units (cfu)/mL. Mice were injected IV (via the tail vein) 
with 0.1 mL of the bacterial suspensions (2-4 x 107cfu, the minimum lethal dose).  The animals 
were then randomized to receive IV isotonic sodium chloride solution (control group), or 1, 1.5, 
3, and 4mg/kg WLBU2 approximately 60min after bacterial challenge.  The animals in each 
group, which included 7-11 mice, were returned to individual cages and subsequently monitored 
for up to 7-10d for survival. The end points of the study were indicated either by 7-10d survival 
or by complete absence of motility as a sign of terminal illness.  
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4.3.5. Evaluation of Treatment 
Quantitative blood cultures on TSA plates were performed to determine bacterial loads over 
the course of the infection. Blood samples were obtained from the tail vein by aseptic 
percutaneous puncture 1h to 24h after bacterial challenge and serially diluted. Then, a 0.1-mL 
volume of each dilution was spread on TSA plates and incubated at 37°C overnight for 
enumeration of developed colonies. Finally, toxicity was evaluated on the basis of the presence 
of drug-related adverse effects such as signs of inflammation, weight loss, and presence of 
bacteria in the blood and tissues. Throughout the course of the infection or at the disease 
endpoint, animals were euthanized, and tissues weighed and homogenized using 70µm cell 
strainers (Becton Dickinson, Franklin Lakes, NJ) to determine bacterial cfu/g tissue.   
 
4.3.6. Statistical Analysis 
Data were analyzed using GraphPad Prism version 3.00 for Windows (GraphPad 
Software, San Diego California USA, www.graphpad.com). Kaplan-Meir survival analysis was 
performed, and the log-rank test used to compare survival between groups. Significance was 
accepted at a P value of <0.05.  
 
4.4. RESULTS 
4.4.1. In Vivo Toxicity 
To characterize the in vivo efficacy of WLBU2, it was important to examine its potential in 
vivo toxicity within a range of concentrations to determine the maximum tolerated dose (MTD). 
We previously described the potential toxicity of WLBU2 in mice when systemically 
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administered. It was found that the maximum tolerated dose of WLBU2, the highest IV dose of 
WLBU2 that caused no obvious toxicity to the mice, was 12mg/kg (Table 5). Of note, no n 
Table 5.  WLBU2 is less toxic than other comparable antimicrobial peptides a 
Colistin
Mice (IV)
<6K6L9
MTD (mg/kg body weight)
<5
12WLBU2
 
aIn three independent studies mice were injected IV with WLBU2, colistin (antimicrobial peptide used 
clinically against Gram-negative bacteria), or K6L9 (antimicrobial peptide in development, with 33% D-
amino acid content). The maximum tolerated dose (MTD) of WLBU2 (12mg/kg) is more than two-fold 
that of colistin (<5mg/kg) and K6L9. 
 
histopathologic changes were observed within 3-5h or 10-21d post-treatment (data not shown). 
As indicated in Table 5, WLBU2 compares favorably with other peptides (colistin and K6L9) that 
have been tested for toxicity in animal models. Colistin is an antimicrobial peptide that is used 
clinically in complicated cases of Gram-negative infections; whereas K6L9 (33% D-amino acid 
content) is a novel CAP that demonstrates significant efficacy in bacteria-infected mice (91). The 
MTD of either colistin or K6L9 is half that of WLBU2. 
Inflammation-induced tissue injury is another measure of host toxicity. Many host-
derived antimicrobial peptides have the property of upregulating cytokine levels. Although 
cytokines may be helpful in alerting key cellular components of the immune system for 
neutralizing infections, inflammatory cytokines often also cause tissue injury and death. 
Antimicrobial peptides may modulate the levels of several potent inflammatory cytokines such 
as IL-1, IL-6, IL-8, and others leading to tissue injury (413, 414, 432). Hence, we attempted to 
characterize the cytokine modulatory property of WLBU2 by comparing cytokine levels in mice 
treated either with heat-killed bacteria or with different doses of WLBU2 after 3h and 5h. As 
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shown in Figure 12A and 12B, the levels of inflammatory cytokines in mice treated with heat-
killed bacteria (HKB) were markedly elevated reaching up to 15 (IL1-β) and 32 (TNF-α) times 
the basal level (control). In contrast, the cytokine levels in WLBU2 (1 or 3mg/kg)-treated mice 
were less than two-fold the basal level (PBS-treated mice) at 3h (Figure 12A and 12B). After 5h 
post-treatment, cytokine levels in WLBU2-treated mice were reduced to basal levels, whereas 
only a partial reduction was observed for HBK-injected mice. These results indicate that 
WLBU2 did not display significant inflammatory property during the first 5h following systemic 
administration. 
 
4.4.2. In Vivo Efficacy 
4.4.2.1. Influence on Survival 
We previously described the efficacy of WLBU2 against P. aeruginosa in an 
intraperitoneal (IP) infection model. The advantage of this model is the induction of a successful 
infection without the need for immune suppression. Mice receiving WLBU2 (2.4mg/kg) were all 
protected against bacterial disease. In this IP model, however, it was not clear whether the 
increased survival observed in WLBU2-treated mice (compared with mock-treated mice) was 
due either to the prevention of bacteremia and septicemia or to the elimination of P. aeruginosa 
infections localized in the internal organs. Hence, we sought to further characterize the in vivo 
efficacy of WLBU2 in an IV infection model.   
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Figure 12. Influence of WLBU2 on Inflammatory Cytokines 
 
To determine the cytokine modulatory property of WLBU2, mice were treated with either PBS, 
heat-killed bacteria (HKB), and 1, or 3mg/kg WLBU2. Mice were sacrificed at 3 and 5h and blood 
samples collected for serum isolation and cytokine quantification as described in Materials and 
Methods. Potent inflammatory responses occurred in mice injected IV with heat-killed bacteria. In 
contrast, WLBU2 had a minor effect on cytokine levels at 3h post-treatment, which was reduced 
to negligible levels by 5h.  
 
 
First, the minimum IV PLD (Pseudomonas lethal dose), the lowest IV bacterial dose (2-3 
x 107 cfu) leading to 100% mortality in 24-30g mice, was determined (data not shown). To 
evaluate the prophylactic effects of WLBU2, the IV PLD was administered to 6 mice 1h after IV 
injection of the peptide. Also included in this experiment are a control (placebo) group (11 mice) 
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receiving isotonic NaCl (PBS) IV 1h post-infection and a therapeutic group (11 mice) given 
3mg/kg WLBU2 IV 1h after bacterial injections (Figure 13).  In comparison with the mock-
treated mice, no lethality was observed in WLBU2-treated groups. Statistical analyses using the 
log-rank test revealed a P value of <0.0001. These results provide strong evidence for a potential 
prophylactic and therapeutic role of WLBU2 in the treatment of P. aeruginosa infections. 
The convincing reproducibility of these data is suggested by the large number of mice (up 
to 11 per group) used; however, it remains unclear how these infected mice would respond to 
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Figure 13. WLBU2 protected mice infected IV with P. aeruginosa  
To characterize the in vivo efficacy of WLBU2, we developed an IV infection model (both PAO1 
and WLBU2 administered IV). After administration of an IV PLD (3-4 x 107 cfu), 11 mice were 
treated with either 3 mg/kg WLBU2 (PAO1 + WLBU2) or PBS at least 1h post-infection. At the 
experimental endpoint, 100% survival was observed for WLBU2-treated mice and no bacterial 
cells were recovered from the blood when compared with 108-109 cfu/ml blood recovered in 
mock-treated mice (data not shown). A log-rank test reveals a P value of <0.0001 when 
comparing survival of WLBU2-treated with that of mock-treated mice. 
 
variable doses of this peptide. To address this issue, P. aeruginosa-infected mice (9 mice/group) 
were treated IV with varying doses (1, 1.5, 3, and 4mg/kg) of peptide 1h post-infection. As 
shown by the Kaplan-Meir survival analysis in Figure 14A, 90% lethality was observed for mice 
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treated with 1.5mg/kg, and the 1mg/kg WLBU2-treated group displayed 100% mortality. In 
contrast, 90 and 100% survival occurred in mice treated systemically with 3 and 4mg/kg, 
respectively. Although the mouse immune system is suspected to play a role in eradicating the  
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Figure 14. Survival and bacterial loads vary with peptide doses 
 
To evaluate the influence of WLBU2 on survival at varying doses, infected mice were treated with 
1, 1.5, 3, and 4mg/kg peptide and followed for up to 7d post-treatment. WLBU2 effectively 
eradicated the infection at a minimum of 3mg/kg (A), with 1 case of fatality of 9 mice treated. 
Mice were also euthanized at 4 and 24h to determine bacterial loads as described in Materials and 
Methods. Bacterial loads increased from 103 (blood) or ~105 (kidney) to 109 cfu per mL blood or g 
tissue in PBS-treated mice. The bacteria were completely eliminated from the blood and tissues by 
4h in mice injected with either 3mg/kg or 4mg/kg WLBU2, which was consistent with survival. 
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infection, the efficacy of WLBU2 is strongly indicated and solely accounts for the difference in 
survival between the control and experimental groups. 
4.4.2.2. Influence on bacterial loads 
During the course of the infection, it was important to evaluate the progression of 
bacterial growth in blood and tissues. Following the administration of a minimum PLD of 2-3x 
107cfu, bacterial loads in the blood initially decreased during the first 3-4h of infection. Typically 
after a dose of 2-3 x 107cfu, the bacterial load in systemic circulation was progressively reduced 
from 106cfu/ml 1h post-infection (not shown) to approximately 103cfu/ml after 4h post-infection 
(Figure 14B). This initial control of bacterial load in the blood of mock-treated mice, however, is 
dependent on the initial dose. In a few cases, PBS-treated mice that were given approximately 
1.5-2x107cfu successfully eliminated the bacteremia while the infection remained localized in the 
organs before the progression to weight loss and terminal disease within 3-4d post-infection 
(data not shown).  Usually in the early phase of infection, bacteria were able to invade the organs 
with bacterial loads varying between 104 and 105cfu/g of tissue in animals treated with either 
PBS or insufficient doses of peptide (1-1.5mg/kg). In contrast, no bacteria were found in the 
blood (Figure 14B). and in the organs of mice treated with 3-4mg/kg WLBU2 1h post-infection 
(Figure 14C). Consistent with our survival analysis, bacterial loads in the organs and blood of 
mice treated with 1-1.5mg/kg after 24h were comparable to those in mice treated with PBS. 
Within 16-24h, signs of terminal illness (lack of motility and hypothermia) began to appear, and 
bacterial loads reached ~109 cfu per mL blood or per gram tissue (Figure 14C). These results 
suggest that WLBU2 plays an important role in helping to control the bacterial infection in 
peptide-treated mice. However, the efficacy of the peptide may be complemented by the mouse 
innate immunity to completely eliminate the bacterial infection. To better understand the 
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significance of these results, we compared the independently determined therapeutic indices of 
WLBU2 and K6L9 against P. aeruginosa. In respective models, WLBU2 displayed a higher 
activity (95-100% survival) in vivo than the D-enantiomer of K6L9 (75% survival) (Table 6). 
 
Table 6. WLBU2 compares favorably with other antibacterial peptides for in vivo efficacy a 
3 x 107
ATCC 
27853
PAO1
Bacterial 
strain
19203IVIV
**6
2.4
Peptide dose 
(mg/kg)
Mice Survivalnumber 
of animals
Route of 
treatment
Route of 
infection
Bacterial 
dose (cfu)
6          8IV*NS 106CD1K6L9
Swiss 
Webster
1414IVIP107
WLBU2
 
 
aThe peptide K6L9, the newest CAP to demonstrate in vivo efficacy against P. aeruginosa, cured 6 
of 8 mice following two equal doses of 3mg/kg as previously described.  WLBU2 cured 14/14 
mice in the IP and 19/20 in the IV infection model at a single dose of 3mg/kg. The bacterial 
infection was completely eradicated within 4 to 24h, which was consistent with no sign of 
disease. *not stated in report; **2 doses of 3mg/kg daily 
 
4.5. Discussion 
We demonstrated that the de novo-derived peptide WLBU2 was highly active against P. 
aeruginosa in vivo. This study was initiated after the observation of WLBU2 activity in human 
blood and serum. First, we evaluated the in vivo toxicity of WLBU2 and showed that mice 
treated with up to 12mg peptide per kg body weight displayed no apparent signs of toxicity. We 
then described the therapeutic efficacy of WLBU2 in an IP infection model. In the current study, 
we demonstrated that WLBU2 was highly prophylactic and therapeutic in an IV infection model 
in a dose-dependent manner. Finally, WLBU2 displayed a slight and transient stimulation of 
some inflammatory cytokines, namely IL1-β and TNF-α. 
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The role of antimicrobial peptides in innate immunity has been long established through 
various studies of the microbial killing mechanisms of neutrophils and macrophages (449, 450, 
452). However, it was not until the last two decades that CAPs have been seriously considered as 
a potential therapeutic source because of the increasing awareness of the problem of multiple 
drug resistance (90, 257, 280). Although numerous CAPs with potent antibacterial efficacy in 
vitro have been identified or engineered, very few have displayed significant activity in animal 
models (91, 312). An important explanation is the suppression of activity in biological 
environments. To address this issue, a series of studies have been initiated in our laboratory to 
develop de novo CAPs for clinical applications. From these studies, we have demonstrated that 
the peptide WLBU2 retained its activity against P. aeruginosa in the presence of physiological 
concentrations of monovalent and divalent cations, human serum, and whole blood. These 
studies warranted further investigations of WLBU2 efficacy in vivo. 
The IP mouse model is one of the most common animal models for testing antibacterial 
efficacy in vivo. Since mice tend to be resistant to chronic P. aeruginosa infection, it is a 
common practice to induce P. aeruginosa dissemination by suppressing the mouse innate 
immunity prior to IP injection of the bacteria (312).  Although the in vivo efficacy of a few CAPs 
is evaluated in this model, we found this system inappropriate for our study. An important reason 
is that some antimicrobial peptides demonstrate cytokine modulation. We thought that some 
other properties of WLBU2 that could influence the outcome of an infection in the context of a 
functional immune system would have been masked by artificially inducing immune 
suppression.  Thus, we were able to successfully develop an IP infection model with a P. 
aeruginosa dose of 107cfu, which is approximately ten times the bacterial dose commonly used 
with concurrent immune suppression (173, 233). In this model with a single dose of 2.4mg/kg 
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administered IV, WLBU2 was able to eliminate the bacteria from the organs and the blood and 
protected all mice from the progression of an acute infection as previously described. However, 
it was not clear whether the peptide was protecting the mouse by sterilizing the systemic 
circulation or by eradicating the initially localized infections. Further, bacteremia is more 
realistic than peritoneal infections in a clinical situation. Thus, we sought to further investigate 
the in vivo efficacy of WLBU2 in an IV infection model.  
 We predicted that the induction of an IV infection would require a lower dose of bacteria 
than that of an IP infection. To our surprise, we had to triple the IP PLD to induce a successful 
IV infection. Infections localized in the internal organs evidently occurred rapidly after the IP 
injection of P. aeruginosa. In contrast, in the IV infection model the direct exposure of bacteria 
to most of the circulating immune cells was likely to result in effective and rapid clearance of 
bacteria from the blood prior to or during dissemination to the organs. This is consistent with the 
concomitant reduction of bacterial load in the blood and increase of bacterial cfu in the organs 
during the first few hours of infection in mock-treated mice. An insufficient dose of WLBU2 
(e.g., 1.5mg/kg) resulted in a transient control of initial bacteremia but not of infections localized 
in the tissues. Evidently, the localized infections served as a new source of bacteria for invasion 
of the systemic circulation leading to death by 36-48h. This explanation is further supported by 
the complete absence of bacteremia in untreated (no peptide) mice injected (IV) with only < 2 x 
107cfu 3-4 days prior to terminal disease. This finding was observed during the determination of 
the IV PLD (data not shown). 
After establishing the IV infection model, the prophylactic potential of WLBU2 (3mg/kg) 
was successfully demonstrated, with the complete prevention of infection. This finding warrants 
further investigation for possible prophylactic antimicrobial application prior to certain surgical 
 90 
procedures. It also provides evidence for peptide stability during at least 1h in systemic 
circulation. Consistent with this observation were the elimination of all bacteria in 11 P. 
aeruginosa-infected mice (in the presence of 3-4mg/kg peptide) and the dose-dependent effect of 
WLBU2 on survival. It was shown that WLBU2 was subtherapeutic at a dose of 1.5mg/kg or 
lower. In contrast, 19 of 20 mice were protected from P. aeruginosa infection by a single IV 
dose of 3mg/kg, and 9 of 9 mice by 4mg/kg. The success of our in vivo models is a remarkable 
advancement in the field of antimicrobial peptide research as indicated by the comparison of the 
efficacy of the peptide K6L9 with that of WLBU2 in Table 6. Our data are not only statistically 
significant (P values <0.0001), but the high number of mice used in comparison with what is 
observed in other in vivo studies is also supportive of the reproducibility of these data (91). 
In a recent study, we characterized the in vivo toxicity of WLBU2 and determined a 
maximum sublethal dose of 12mg/kg. What remained unclear was whether WLBU2 could 
potentially cause tissue injury by upregulating the levels of potent inflammatory cytokines, a 
property of some antimicrobial peptides (24, 432). Judging by the important role of cytokines in 
host defense, there are obviously some benefits to cytokine stimulation by natural CAPs. 
However, during the progression of bacterial disease, the stimulation of potent inflammatory 
responses is generally undesired for the sake of preserving tissue integrity and preventing 
disseminated intravascular coagulation. Thus, from a clinical standpoint the anti-inflammatory 
property of an antimicrobial drug is preferred. It is from this perspective that we tested the 
influence of WLBU2 on cytokine levels. From an extensive panel of cytokines analyzed, IL1-β 
and TNF-α were given more attention because of their importance in systemic inflammation and 
the notable changes in their levels compared to other cytokines. WLBU2 displayed only a minor 
stimulation of these two cytokines. These results demonstrated that the inflammatory property of 
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WLBU2 would not be a concern in its eventual use against clinical diseases caused by P. 
aeruginosa. 
Taken together, our data demonstrate the successful development of a P. aeruginosa 
bacteremic model in the context of a competent immune system. Using this model, we were able 
to show that the de novo-derived CAP was highly prophylactic and therapeutic against P. 
aeruginosa bacteremia in mice. WLBU2 compares favorably with the standard antimicrobial 
peptide colistin and the novel CAP K6L9 (91). These results provide fundamental information 
that may be useful for evaluating in vivo efficacy of other CAPs. Further, the data underscore the 
need for comparative studies of WLBU2 and standard antimicrobials in similar mouse models to 
establish a potential for clinical trials.  
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5. CHAPTER 5: Overall Discussion 
 
5.1. Overall Summary 
The ubiquity of antimicrobial peptides and their role in host immunity suggest that they 
could be used as an additional source of agents with novel antimicrobial mechanisms against 
MDR pathogens. Despite extensive efforts to develop CAPs for clinical use, the preservation of 
CAP activity in biological environments remains a tremendous challenge. In the first aim, we 
demonstrated the design of antimicrobial peptides with potent antibacterial activity based on a 
cationic amphipathic motif (LBU) by using solely Arg on the cationic face and Val residues on 
the hydrophobic face. Antibacterial activity positively correlated with helicity and length, but no 
net gain in activity was observed for peptides longer than 24 residues. Not surprisingly, the 
inclusion of Trp residues on the hydrophobic face improved the activity of the 24-mer LBU2 as 
predicted. The LBU derivative WLBU2 was identified as the lead compound and retained 
optimal active against a battery of 16 clinical isolates of P. aeruginosa.  
The second objective was to compare the in vitro efficacy of the natural antimicrobial 
peptide LL37 with that of WLBU2 under biologically relevant conditions. The activity of LL37 
was consistently suppressed in the presence of increasing concentrations of Mg2+ and Ca2+ and in 
human serum. In contrast, WLBU2 activity was refractory to physiological concentrations of 
these cations. A remarkable finding was the complete killing of P. aeruginosa by WLBU2 in 
human serum and whole blood, without adverse effects on host cells. These results formed the 
basis for evaluating the efficacy of WLBU2 in experimental mouse models.  
The final aim was to investigate the in vivo efficacy of WLBU2. First, we determined the 
MTD of the peptide to identify a range of potential therapeutic doses. In the IP infection model, 
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we established an effective therapeutic dose of 2.4mg/kg body weight (1/6 MTD). Then we were  
able to show that WLBU2 was both prophylactic and therapeutic in an IV infection model in a 
dose-dependent manner. Furthermore, WLBU2 only slightly stimulated the inflammatory 
cytokines IL1-β and TNF-α. 
5.2. Peptide Design 
To develop potent antimicrobial peptides, two main approaches have been used. One is to 
evaluate host-derived antimicrobial peptides for a better understanding of the structural 
determinants of biological activity and for improved potency (394, 396). The other is to apply 
the lessons derived from these studies to de novo engineering of CAPs with higher antibacterial 
activity (286, 365, 400). Studies of several CAPs identified some fundamental structure-function 
specificities. Antimicrobial peptides are typically short (10-50 amino acid residues), and they all 
fold into amphipathic structures in the presence of lipid membranes or membrane mimetic 
environments (48, 59, 443, 444). Although a consensus sequence has not been identified, specific 
amino acids may be associated with antimicrobial activity. Either Arg or Lys (or both) is 
commonly found in the hydrophilic domains of natural CAPs (178, 352, 353). The hydrophobic 
amino acids Val (e.g., LLP1), and Trp (e.g., indolicidin), and few others are also common (9, 10, 
226, 352, 353, 394, 416). Various studies indicate that selective toxicity is maintained by a 
balance between cationicity and the level of hydrophobicity. While increasing cationicity may 
enhance selective toxicity against Gram-negative organisms, raising the level of hydrophobicity 
may have a greater impact on Gram-positive bacteria and increase host toxicity (153, 154, 189, 
217, 307, 359, 425). Consistent with these studies is the increased potency of LLP1 derivatives 
with higher Arg and Val content and Trp substitution (330).  
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An important consideration in peptide design is the minimum length required for optimal 
antimicrobial activity to minimize the cost of production. McLaughlin and co-workers initiated 
the concept of multimeric peptide design from a unique sequence(251).  Although most natural 
peptides are short (usually <50 amino acids), it is not possible to predict the minimum length for 
optimal activity based on this observation alone, and natural peptides do not necessarily require 
the membrane spanning length of 22 residues for activity. Thus, it was necessary to adopt an 
approach consisting of varying length without considerably changing the primary sequence. 
There were a few studies of de novo engineered peptides demonstrating activity at 20 amino 
acids or less, but most of these were not comparative studies based on length variation (252, 286, 
400).  McLaughlin and colleagues were able to generate a multimeric series of peptides based on 
a 7-residue primary sequence (252). However, a maximum length of only 21 residues was used 
and no conclusion could be drawn about longer peptides of similar sequence.  Thus, we decided 
to extend this multimeric concept to 48 residues based on an LBU length of 12 residues. The 
amino acids Arg and Val were used due to their large proportion in LLP1, and Trp residues were 
substituted at a intervals of at least 7 amino acids to avoid disrupting the predicted helical 
structure (396). Using a helical wheel analysis for the generation of idealized amphipathic 
helices, the LBU peptides were engineered with Arg and Val maximally segregated into 
hydrophilic and hydrophobic faces, respectively. Given the membrane-seeking property of Trp, it 
was possible to predict an improvement in potency with Trp-containing peptides (354). Hence 
the WLBU peptides were derived from the parent LBUs by Trp substitution. 
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5.3. Structural Determinants of Antimicrobial Activity 
Length & helicity: Prior to the design of the LBU and WLBU series, only few engineered 
peptides with antimicrobial activity were reported. Whether the focus was on cyclic or linear 
CAPs, the amphipathic motif was a common feature, but the influence of length on activity 
remained unclear (68, 286, 447). Javadpour et al. demonstrated a positive correlation between 
length and activity using the aforementioned multimeric peptide series, but they limited the 
maximum length to 21 residues (252).  Similar to this study, our data have shown a positive 
correlation between length and activity. However, by extending the length of the LBU peptides 
to 48 residues, we were able to demonstrate that optimal activity could be achieved at 24 
residues. We predicted that the 48-mer would be by far the most potent based on the fact that 
charge and hydrophobicity increase with length. Contrary to this hypothesis, we found that the 
cationic and hydrophobic densities (rather than the overall charge and hydrophobicity), coupled 
with an optimal membrane spanning region (>22 residues), account for the optimal activity 
achieved by LBU2.  
The helical propensity of the peptides also had a major influence on activity. Expanding 
the peptides from 12 to 24 residues more than tripled the helicity. Studies of interactions of 
antimicrobial peptides with model membranes indicate that induction of the native conformation 
of a particular CAP is essential to pore-forming or cell penetration activity (178, 250, 326, 352, 
369, 372, 373, 416, 422). A recent study by Park et al. suggests that the disruption of the helical 
structure suppresses activity. It was shown that stabilizing the helical structure with a helix-
capping motif significantly enhanced activity in the presence of high salt concentrations (327). 
Furthermore, several studies demonstrate that CAPs interact more strongly with negatively 
charged than with zwitterionic model membranes (8, 11, 55, 73, 74, 145, 160, 444).  Considering 
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that LBU2 has the strongest cationic density (13 + charges over a total of 24 residues), it is not 
surprising that optimal antimicrobial activity was achieved at 24 residues.  
Trp & activity: Similar to the relationship between activity, length, and helicity in the LBU 
series, the 24-mer WLBU was the most potent of the WLBU peptides. It has the same cationic 
density, amphipathicity, and helical propensity as LBU2. But the three Trp residues in the 
hydrophobic face considerably enhanced the activity of WLBU2 against S. aureus in the 
presence or absence of salt while maintaining optimal efficacy against P. aeruginosa. Circular 
dichroism analysis reveals no change in the helical structure of WLBU2 compared with that of 
the parent LBU2.  The importance of Trp in CAPs is supported by other reports. For instance, 
Vogel and others have shown that Trp and Arg residues in lactoferricin or indolicidin are 
essential to antimicrobial activity. Other evidence is also provided by studies of engineered Arg- 
and Trp-containing peptides (179, 256, 352, 353, 416). The antistaphylococcal activity of LBU2 
was suppressed in the presence of 150mM NaCl. In contrast, WLBU2 displayed potent activity 
against both Gram-negative and –positive bacteria in the presence of physiological 
concentrations of monovalent and divalent cations.  Several studies support these differences 
between the two peptides. For instance, some CAPs display more affinity for the LPS-containing 
bacterial membrane than for Gram-positive membrane (99, 189, 190, 228, 266, 307, 386, 387, 
418, 419, 421, 426). Similarly, in the presence of salt LBU2 is able to bind strongly to the 
negatively charged LPS. However, at the same concentration NaCl disrupts this interaction with 
the less negatively charged surface of S. aureus.  Under this condition, it’s highly likely that 
LBU2 adopts a random coil conformation. The inclusion of 3 Trp residues in the hydrophobic 
face of LBU2 results in higher membrane affinity. Park et al. demonstrated that a helix capping 
motif conferred helical stability and preservation of activity in high salt environment. Similarly,  
 97 
a salt environment, being less ideal to a Trp-containing peptide, should favor the native helical 
conformation in the presence of a lipid bilayer (11, 116, 188, 255, 267). Thus, WLBU2 displayed 
potent efficacy against both S. aureus and P. aeruginosa, and salt sensitivity may be overcome 
by using Trp substitution in pre-existing antimicrobial peptides. 
 
5.3.1. Structural Determinants of Selective Toxicity 
Another challenge to the development of CAPs for clinical use is the suppression of 
activity in human serum (152). The discovery of the magainins and their broad antibacterial 
activity made magainin derivatives very promising as prospective clinical agents. However, the 
lack of activity of magainin 2 against P. aeruginosa bacteremia in mice and other findings that 
were consistent with this observation shifted CAP development toward topical applications (205, 
339). To date, there have been few reports on CAP activity in biological fluids. In 2004, when 
the data on the activity of WLBU2 in human blood were not yet published, a group of 
investigators reported the activity of platelet-derived peptides in human blood and blood-derived 
matrices (393, 434, 436). Two years prior to that report, we designed a series of experiments to 
examine the selective property of WLBU2 in biological fluids. The standard RBC lysis assay in 
PBS was too artificial to predict the behavior of WLBU2 in a real drug-pathogen interaction. 
Further, bacterial and host toxicity assays performed independently cannot necessarily evaluate 
the selective property of a drug in the context of an infection. Thus, we developed the concept of 
selective toxicity in the context of a competition between the host and the pathogen co-existing 
either in human blood or serum. We were able to show that the activity of the human synthetic 
peptide LL37 was markedly suppressed in human serum and whole blood. In contrast, WLBU2 
achieved complete killing in serum by 20min and was selectively toxic toward P. aeruginosa in 
 98 
blood and in a co-culture of P. aeruginosa and human monocytes. These results ultimately led to 
the systemic evaluation of the efficacy of WLBU2 in experimental mouse models. 
 
5.4. Progress toward Systemic Application of WLBU2 
Because of limitations previously mentioned, there have been few published reports on 
the in vivo efficacy of antimicrobial peptides. One recent study describes the antipseudomonal 
activity of the peptide dermaseptin S4 in the murine peritoneal space; however, this was just a 
small advancement over a test tube model (312). To test the in vivo efficacy of the de novo-
derived peptide WLBU2, we developed an IP-induced bacteremic model and demonstrated 
potent antipseudomonal efficacy of WLBU2 at 2.4mg/kg. To protect 14 mice with a single dose 
IV was an exceptional advancement in the field of antimicrobial peptide research.  
The lack of reports on the systemic use of CAPs is not indicative of a lack of in vivo 
studies. It is likely that unsuccessful attempts to demonstrate the in vivo activity of engineered 
CAPs were reported. One possible reason for this lack of success is the short half life of 
antimicrobial peptides. This issue was addressed in a recent study of a CAP containing 33% D-
amino acids (91). After displaying potent activity over the ineffective L-enantiomer in the 
presence of human serum, this peptide (injected IV) was shown to cure 6 of 8 (75%) P. 
aeruginosa-infected mice. We addressed the issue of a short half life in a different way. We 
demonstrated that WLBU2 (3mg/kg) was able to protect Swiss Webster mice against the 
development of bacteremia when administered IV 1h prior to bacterial injection. This finding 
suggests that the L-enantiomer of WLBU2 remained active in the murine circulatory system for 
at least 1h post-treatment.  The efficacy of the L-enantiomer will reduce cost by eliminating the 
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need for the more expensive D-amino acids. Further, WLBU2 could be explored as a 
prophylactic agent in procedures with high risk for bacterial infection.  
In our dose-dependent survival analysis, we demonstrated a minimum therapeutic dose of 
3mg/kg. A total of 19/20 and 9/9 mice were successfully cured by 3mg/kg and 4mg/kg WLBU2, 
respectively; this is about 1/5 to 1/4 of the MTD. It is important to note that the previously tested 
peptides have a narrower therapeutic window. For instance, the CAP K6L9 gave rise to 75% 
survival with 2 doses of 3mg/kg. Evidently, a single dose would be nontherapeutic and the 
peptide is toxic at higher doses.   
Together with the low stimulatory effect on inflammatory cytokines, the in vivo efficacy 
of WLBU2 in the IP and IV infection models underlines the need to further investigate WLBU2 
as a potential therapeutic against P. aeruginosa infections. 
 
5.5. Future Directions 
Our study of de novo antimicrobial peptides has provided many answers, but several issues still 
need to be addressed in the areas of peptide design and progress toward clinical applications. 
 
5.5.1. Peptide Design and Evaluation 
Based on the literature on antimicrobial peptides, our data indicate that WLBU2 is the 
most extensively characterized and the most potent de novo-derived CAP. However, the lessons 
derived from the development of WLBU2 could be used to generate CAPs with greater 
therapeutic indices. We now have a better understanding of how to balance cationic density and 
hydrophobicity to design potent CAPs with low mammalian cytotoxicity. In our laboratory, there 
have been some efforts to design better WLBU peptides by replacing all the Val with Trp 
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residues in the hydrophobic face. Although a 24-mer with 11 Trp residues would be considerably 
more potent, it is highly likely that this peptide would display significant host toxicity. One way 
to overcome this problem is to create shorter WLBU peptides. Thus a 12- and 24-mers have 
already been synthesized, and their antibacterial efficacy will be soon evaluated. However, to 
completely explore this peptide series for improving the therapeutic window, the synthesis of 
more WLBU peptides differing by only 3 residues in length is warranted. For instance, we could 
create Arg-Trp peptides with 6, 9, 12, 15, 18, and 21 residues using the helical wheel analysis. In 
addition, some Trp residues could be replaced with Val in the most potent peptides to reduce 
mammalian toxicity, a reverse approach to that used in the initial design of the WLBU series. 
The smallest peptides (e.g, 6, 9 residues) could be made circular by introducing two Cys residues 
at the N- and C-termini or oligomeric by adding one Cys residue at either end of the peptide.  
The results of these studies could potentially lead to shorter peptides with similar potency to 
WLBU2 but with lower potential for host toxicity. It will take several years to design the WLBU 
peptides and evaluate their antimicrobial efficacy. However, because we have already developed 
the methodology, it should be less time consuming to examine selective toxicity, structural 
analysis, and in vivo efficacy. 
 
5.5.2. Progress toward Clinical Applications 
5.5.2.1. Treatment of Bacteremia  
 
The convincing evidence for the potential application of WLBU2 to P. aeruginosa 
infections does not preclude further evaluation of the efficacy of this peptide in animal 
models. Because of biological differences between humans and mice, it is important to 
compare (in our mouse models) the efficacy of WLBU2 with that of standard antibiotics. 
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The polymyxins (e.g., colistin) are the most common family of CAPs used clinically 
against Gram-negative infections, and tobramycin is a standard antipseudomonal agent. 
Some comparative studies between WLBU2, colistin, and tobramycin have already been 
initiated in Dr. Mietzner’s laboratory (Omar Bakth) (137, 293, 305). WLBU2 (at much 
lower concentrations than colistin) demonstrated zones of bacterial growth inhibition 
comparable to those of colistin on agar plates against a tobramycin-resistant P. aeruginosa 
strain. It would be very informative to compare these three antimicrobial agents in our in 
vivo models against both tobramycin-sensitive and -resistant strains of P. aeruginosa. 
These studies could be concluded by comparative analysis of the pharmacokinetics of 
colistin and WLBU2. Such studies would provide fundamental information from which to 
predict the potential therapeutic effect of WLBU2 in a clinical setting. 
 
5.5.2.2. Treatment of Lung infections 
P. aeruginosa can colonize a variety of tissues, but it is most known for causing lung 
infections (pneumonia) (347). The application of WLBU2 to the treatment of lung infections 
could serve as an effective alternative therapy against MDR P. aeruginosa, particularly in CF 
and ventilator-associated pneumonia patients. An intratracheal (IT) infection model is currently 
being developed in collaboration with Dr. Jay Kolls (Children’s Hospital, Pittsburgh, PA). In this 
model, both bacteria and peptide will be administered (in sequence) IT. Alternatively, the 
bacterial suspensions or the peptide (or both) could be given directly through the murine airway 
by nebulization. The method of aerosolization, although more technically complex, would be 
more reflective of a real clinical situation than the IT infection. A third approach would be to 
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deliver the peptide systemically. The advantage of the aerosolization and the systemic methods 
of administration is that they are both clinically applicable. 
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5.5.2.3. Application to Infections Associated with the Implantation of Medical Devices 
(Prophylaxis) 
 We have already demonstrated the in vivo prophylactic potential of WLBU2. In 
addition, other unpublished data from our laboratory have shown that resin-bound WLBU2 can 
rapidly sterilize a P. aeruginosa suspension in PBS (Omar Bakth). Our laboratory is planning to 
investigate the influence of WLBU2 on biofilm formation inside a catheter in vivo. The 
exploration of this avenue may lead to the prevention of infections associated with the 
implantation of medical devices.  
 In conclusion, although antimicrobial peptides must be developed in the context of 
specific applications, it is evident from the results of our current investigations that WLBU2 can 
be evaluated for several clinical applications. However, the significant changes in therapeutic 
effects due to small variations in peptide doses observed in our experimental models are unlikely 
to occur in humans.  Therefore, it is imperative to use a larger range of peptide doses in future 
models to establish more accurately a therapeutic window for WLBU2.  
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